| Entries |
| Document | Title | Date |
|---|
| 20120010152 | Targeting of Podoplanin with Lectin for Use in the Prevention and Treatment of Cancer - Lectin compositions and methods for reducing tumor cell growth and preventing or treating cancer are provided. | 01-12-2012 |
| 20160016994 | INHIBITION OF TUMOR GROWTH WITH AGGREGATES OF SMALL MOLECULES - Disclosed herein are fibrillar molecular aggregates, which are morphologically and phenotypically similar to oligomers of aberrant proteins. The molecular aggregates, formed by self-assembly of small hydrophobic molecules, prevent the growth of microtubules. This unprecedented mechanism of “self-assembly to interfere with self-organization” allows inhibition of the growth of cancer cells. | 01-21-2016 |
| 20150105326 | METHYL DEGRON PEPTIDE AND METHODS OF CONTROLLING PROTEIN LIFESPAN - The present invention provides an isolated methyl degron peptide and a fusion protein comprising a methyl degron peptide. Also, the present invention provides screening methods for agents affecting protein lifespan and anti-cancer agents. Moreover, the present invention provides methods of controlling protein lifespan, regulating protein expression, and treating cancers by using a methyl degron peptide or a methyl degron gene. | 04-16-2015 |
| 20160015710 | Methods of Treating Multiple Myeloma and Resistant Cancers - Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 01-21-2016 |
| 20160015700 | 4-CYANO-N-(2-(4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)-6-(2,2,6,6-TETRAMETHYLTETRAH- YDRO-2H-PYRAN-4-YL)PYRIDIN-3-YL)-1H-IMIDAZOLE-2-CARBOXAMIDE FOR THE TREATMENT OF HODGKIN'S LYMPHOMA - The present invention is directed to methods for the treatment of Hodgkin's lymphoma comprising administering to a patient in need thereof, a therapeutically effective amount of 4-cyano-N-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6 -(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1H-imidazole-2-carboxamide as mono-therapy or as combination or co-therapy with one or more chemotherapeutic agent or chemotherapy regimens. | 01-21-2016 |
| 20130324479 | METHODS FOR INDUCING EPITHELIAL CANCER CELL SENESCENCE - Systems, methods, and computer readable media for diagnosing or characterizing epithelial cancer or its stages based on the level of expression of the Wnt5a gene or protein are provided. The level of nucleic acids encoding Wnt5a or the level of Wnt5a protein is measured in a tissue sample, and the level is compared with reference values. Methods for inducing senescence of an epithelial cancer cell are also provided. | 12-05-2013 |
| 20130324478 | Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration - The present invention relates to the field of medicine and biology. It concerns a new test for screening and therapeutic follow-up in oncology. More particularly, it relates to diagnostic and/or therapeutic tests in oncology and on neurodegenerative diseases. Molecular targeting by peptide vectors and antibodies or by small interfering RNAs (siRNAs) opens a new concept of interdependence for diagnostic and therapeutic tools. | 12-05-2013 |
| 20130190248 | SUBSTITUTED PEPTIDE ANALOGS - The present invention relates to peptide analogs, antibody-drug conjugates comprising such compounds, pharmaceutical compositions comprising such compounds and conjugates, and methods of treating cancer with such compounds and conjugates. | 07-25-2013 |
| 20140088021 | Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds - Compounds comprising a binding moiety, water-soluble, non-peptidic polymer, and drug are provided. Also provided are methods preparing such compounds, compositions comprising such compounds and methods for administering and using such compounds and compositions. | 03-27-2014 |
| 20140088018 | COMPOSITIONS AND METHODS FOR TREATMENT OF GYNECOLOGIC CANCERS - Molecules and compositions that can be used in the treatment of gynecologic cancers are described. ApoA-1, in particular, is demonstrated to inhibit the proliferation of cancer cells reduce tumor size in a mouse model of ovarian cancer. | 03-27-2014 |
| 20130225502 | COMBINATION THERAPY WITH W T 1 PEPTIDE VACCINE AND TEMOZOLOMIDE - The present invention relates to combination therapy for cancer with a WT1 peptide vaccine and temozolomide. | 08-29-2013 |
| 20150038429 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY - The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4′-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment. | 02-05-2015 |
| 20120184495 | TARGETED NANO-PHOTOMEDICINES FOR PHOTODYNAMIC THERAPY OF CANCER - The present invention relates to a photosensitizer-containing nanoparticle, comprising a photosensitizer covalently bonded throughout at least a part of said nanoparticle to the nanoparticle matrix material and incorporated therein in a quasi-aggregated state. The present invention further relates to methods for producing the invention nanoparticles, and to methods of killing cancer cells by PDT treatment using the said nanoparticles. | 07-19-2012 |
| 20110015133 | PAX2 AND PAX8 AS TUMOUR TARGETS FOR IMMUNOLOGIC AND MOLECULAR TREATMENT STRATEGIES - Briefly, the present invention refers to the transcription factors PAX2 and PAX8 expressed in solid tumours and haematologic malignancies, and their utility as a target in immunotherapy and molecular therapy. In more detail, the invention refers to a method for identifying an immunogenic T-cell epitope from PAX2 and/or PAX8. Furthermore, the invention refers to a use of immunogenic T-cell epitopes, e.g. identified by said method, and their use as targets for the recognition by targeting means, e.g. T-cells or antibodies. The invention also refers to peptides representing immunogenic T-cell epitopes and their uses for the preparation of a pharmaceutical composition for immunotherapy of PAX2 and/or PAX8 expressing malignancies. | 01-20-2011 |
| 20110015134 | Method of treatment for early stage cancer - This patent describes a method and materials to treat cancer diagnosed at an early stage, particularly breast cancer. It considers that metastatic breast cancer growth includes periods of dormancy, that surgery to remove a primary tumor can induce metastatic growth, and that women with Down Syndrome rarely get breast cancer. It elevates the level of an antiangiogenic drug produced by chromosome 21 preferably Endostatin in plasma preferably at least one day prior to surgery and kept at that high level preferably indefinitely. In one embodiment, the therapy specifically excludes drugs that significantly inhibit the VEGF pathway since that is important for wound healing. This method will prevent results of surgery from stimulating tumor growth and angiogenesis of micrometastatic disease that is much easier to prevent than control after the fact. This can be done indefinitely since there is no acquired resistance that develops, as happens in most cancer therapies. | 01-20-2011 |
| 20120220538 | LUNASIN-CONTAINING COMPLEX AND PURIFICATION OF LUNASIN FROM PLANTS - A method of purifying lunasin or a lunasin-containing complex produced in a plant includes providing a plant material from the plant, and isolating the lunasin-containing complex from the plant material, and/or releasing lunasin from the lunasin-containing complex. A composition for treating a cancer or an inflammation-related disease in a subject includes a lunasin-containing complex. A composition for treating a cancer or an inflammation-related disease in a subject includes a lunasin polypeptide and/or a lunasin-containing complex; and curcumin, wherein the combination of the a lunasin polypeptide or lunasin-containing complex and the curcumin has a synergistic effect. A method for treating a cancer or an inflammation-related disease includes administering a composition including a lunasin-containing complex, or a lunasin polypeptide and/or a lunasin-containing complex, and curcumin. | 08-30-2012 |
| 20110046068 | Compound, Use and Method - The present invention relates to the use of an antagonist of kisspeptin in the manufacture of a medicament for the treatment of a condition induced and/or worsened by kisspeptin activity in an individual. The invention also provides certain defined peptide molecules, which may act as an antagonist of kisspeptin, which are of use in treating a condition induced and/or worsened by kisspeptin activity in an individual. In addition, the invention provides methods of identifying and/or using antagonists of kisspeptin and/or the defined peptides, and pharmaceutical compositions thereof. | 02-24-2011 |
| 20150148298 | N-CARBOXYALKYL-AURISTATIN AND USE THEREOF - The present application relates to new derivatives of monomethylauristatin F, substituted on the N terminus by a carboxyalkyl group, processes for preparing these derivatives, their use for the treatment and/or prevention of diseases and to produce medication for the treatment and/or prevention of diseases, particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments can occur as monotherapies or in combination with other medication or further therapeutic measures. | 05-28-2015 |
| 20110009335 | Anticancer Treatments - The present invention relates to combinations of aplidine with another anticancer drug selected from sorafenib, temsirolimus, and sunitinib, and the use of these combinations in the treatment of cancer. | 01-13-2011 |
| 20150314010 | POTENTIATION OF ANTICANCER AGENTS - The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer. | 11-05-2015 |
| 20100249039 | Methods for Treating Cancer Using an Immunotoxin - The present invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using VB4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of | 09-30-2010 |
| 20120071418 | Inhibitors of Human EZH2 and Methods of Use Thereof - The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject. | 03-22-2012 |
| 20130005663 | SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS - The present invention is directed to a compound of the formula: | 01-03-2013 |
| 20110077205 | Production and Use of Antitumoral Cyclodepsipeptides - A compound having the general structure | 03-31-2011 |
| 20110034398 | USE OF IMP3 AS A PROGNOSTIC MARKER FOR CANCER - Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided. | 02-10-2011 |
| 20120178697 | Compositions and methods for the inhibition of dishevelled proteins - The Wnt signaling pathways are involved in embryo development as well as in tumorigenesis. Dishevelled (Dvl) tranduces Wnt signals from the receptor Frizzled (Fz) to downstream components in canonical and non-canonical Wnt signaling pathways, and the Dvl PDZ domain plays an essential role in both pathways, and the Dvl PDZ domain binds directly to Fz receptors. In the present invention using NMR-assisted virtual ligand screening, several compounds were identified and were found to bind to the Dvl PDZ domain. Molecular dynamics simulation was used to analyze the binding between the PDZ domain and these compounds in detail. These compounds provide a basis for rational design of high-affinity inhibitors of the PDZ domain, which can block Wnt signaling by interrupting the Fz-Dvl interaction. | 07-12-2012 |
| 20110082088 | COMBINATION THERAPY FOR PANCREATIC CANCER USING AN ANTIGENIC PEPTIDE AND CHEMOTHERAPEUTIC AGENT - Described herein is a combination therapy suited to the treatment of pancreatic cancer and the like. Also described is a method of potentiating the therapeutic effect of chemotherapeutic agents such as gemcitabine. | 04-07-2011 |
| 20110082090 | COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE - The invention relates to a compound suited as entity carrier, having the general formula (I) | 04-07-2011 |
| 20160115203 | HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF - Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits. | 04-28-2016 |
| 20120129787 | Modified oligopeptides with anticancer properties and methods of obtaining them - This invention may be used in human and veterinary medicine for the creation of a drug that is effective perorally in the treatment of oncological illnesses. | 05-24-2012 |
| 20120190628 | GENES AND POLYPEPTIDES RELATING TO HUMAN COLON CANCERS - The present application provides novel human genes RNF43 whose expression is markedly elevated in colorectal cancers, as well as CXADRL1 and GCUD1 whose expression is markedly elevated in gastric cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease. | 07-26-2012 |
| 20110021440 | APOPTOTIC PATHWAY TARGETING FOR THE DIAGNOSIS AND TREATMENT OF CANCER - The invention relates to methods of treating cancer. The invention further relates to a method of treating cancer by exploiting apoptotic pathways. The invention particularly relates to regulation of apoptotic pathways in cancerous cells, to metastasis of cancer cells, and to methods of preventing cancer metastasis. | 01-27-2011 |
| 20120035114 | INHIBITORS OF STAT3 AND USES THEREOF - Compounds which inhibit the activity of signal transducer and activator of transcription 3 (STAT3) are provided together with methods of making and using the same. The compounds are designed to bind to the SH2 domain of STAT3, preventing STAT3 from binding to receptors for interleukin-6 family cytokines, growth factors such as the platelet-derived growth factor, the epidermal growth factor, vascular endothelial growth factor, and other signaling molecules such as leptin. Blocking these interactions prevents STAT3 from being phosphorylated on Tyr705, which is required for the dimerization of STAT3, translocation to the nucleus, binding to STAT3 response elements on promotors, and transcription of genes. In addition to these activities, binding to the SH2 domain of STAT3 breaks up pre-formed dimmers, thereby preventing the transcriptional activity of the inhibitor. | 02-09-2012 |
| 20110105407 | Tissue Inhibitor of Metalloproteinases (Timp) Linked to Glycosylphosphatidylinositol (Gpi) - Anchors for Treatment of Cancer and Skin Lesions - The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI)-anchored tissue inhibitors of metalloproteinases (TIMPs) and their use for the treatment of cancer and in regenerative medicine. By this approach, the GPI-anchored TIMP proteins are incorporated into the surface membrane of tumor cells and render tumor cells sensitive to FAS-induced apoptosis. Furthermore, the fusion constructs of the present invention are effective agents useful in wound healing applications. In one embodiment, the TIMP is linked to mucin followed by GPI in order to enhance surface presentation. The use of GPI to link TIMP renders the resulting fusion protein particularly useful as an anti-cancer agent for the treatment of cancer, and, in particular, any residual cancer following an incomplete surgical resection of primary tumors in an individual. | 05-05-2011 |
| 20150322111 | IAP ANTAGONISTS - There are disclosed compounds of formula (I) that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. | 11-12-2015 |
| 20140206620 | T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials. | 07-24-2014 |
| 20110046069 | Uses of Modified ELR-CXC Chemokine G31P - Described herein is the use of a modified human chemokine, GS-CXCL8 | 02-24-2011 |
| 20160083441 | Development of Protein-Based Biotherapeutics That Penetrate Cell-Membrane and Induce Anti-Cancer Effect - Cell-Permeable Trefoil Factor 1 (CP-TFF1) in Gastrointestinal Track (GIT) Cancer, Polynucleotides Encoding The Same, and Anti-Cancer Compositions Comprising The Same - The present study investigated the use of macromolecule intracellular transduction technology (MITT) to deliver biologically active TFF1 protein into gastric cancer cells both in vitro and in vivo. Proteins engineered to enter cancer cells are supposed to suppress cell proliferation and survival, consistent with its role as a tumor suppressor. The invention has developed new hydrophobic CPP-advanced MTDs (aMTDs) for high solubility/yield and cell-/tissue-permeability of the recombinant therapeutic fusion proteins. The TFF1 protein has been fused to aMTD165 and solubilization domains (SDs), and tested their therapeutic applicability as a gastric cancer-specific protein-based anti-cancer agent. Treatment with CP-TFF1 in gastric cancer cells reduced cancer cell viability (60%˜80% in 10 μM treatment), inhibited cell migration (approximately 50%). Furthermore, CP-TFF1 significantly inhibited the tumor growth during the treatment and the effect persisted for at least 3 weeks after the treatment was terminated (90% inhibition at day 42) in a xenografts model which were subcutaneously implanted with tumor block of gastric cancer cells (MKN45). In the present invention, CP-TFF1 recombinant protein showed the potential of novel protein therapies against gastric cancer. | 03-24-2016 |
| 20140024601 | CHIMERIC IMMUNORECEPTOR USEFUL IN TREATING HUMAN CANCERS - The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain. | 01-23-2014 |
| 20110046067 | COMPOSITIONS COMPRISING HUMAN EGFR-siRNA AND METHODS OF USE - The present invention provides nucleic acid molecules that inhibit EGFR expression. Methods of using the nucleic acid molecules are also provided. | 02-24-2011 |
| 20110086806 | Polypeptides that Bind IL-23R - Polypeptides that bind to IL-23R including polypeptides having a multimerizing, e.g. trimerizing, domain and a polypeptide sequence that binds IL-23R. The multimerizing domain may be derived from human tetranectin. IL-23R binding polypeptides inhibit activation of IL-23R by native IL-23 and can be used as therapeutics agents for a variety of immune related disorders and cancers. Methods for selecting polypeptides and preparing multimeric complexes are described. | 04-14-2011 |
| 20100279949 | Process for preparing recombinant heterocarpine - A process for preparing recombinant heterocarpine with the complete sequence of heterocarpine (SEQ. ID. NO. 10), expression vectors comprising a polynucleotide encoding for heterocarpine, host cells transformed or transfected by said expression vectors as well as a process for obtaining heterocarpine by means of said transformed or transfected host cells are described wherein the recombinant heterocarpine obtained is used to treat cancer. | 11-04-2010 |
| 20110092441 | CELL-PERMEABLE ENDOSTATIN RECOMBINANT PROTEIN, A POLYNUCLEOTIDE ENCODING THE SAME, AND AN ANTI-CANCER PREPARATION CONTAINING THE SAME AS AN ACTIVE COMPONENT - The present invention relates to a cell-permeable endostatin recombinant protein in which a macromolecule transduction domain (MTD) is fused to an angiogenesis inhibitor (angiogenesis inhibitor) endostatin; a polynucleotide encoding the cell-permeable endostatin recombinant protein; an expression vector for the cell-permeable endostatin recombinant protein; and a pharmacological composition for an anti-cancer preparation with improved inhibitory activity against angiogenesis in cancer, which contains the cell-permeable endostatin recombinant protein as an active component. The cell-permeable endostatin recombinant protein according to the present invention can block the formation of microvessels and inhibit the migration, proliferation, penetration, tube formation and the like of vascular endothelial cells present in tumor tissue by introducing the angiogenesis inhibitor endostatin into the cell with high efficiency, and it exhibits outstanding anti-cancer activity and so can be used as an anti-cancer drug against various cancers. | 04-21-2011 |
| 20110059901 | Compositions and Methods for Treatment of Neoplastic Disease - The present invention comprises compositions and methods for treating a tumor or neoplastic disease in a host, The methods employ conjugates comprising superantigen polypeptides or nucleic acids with other structures that preferentially bind to tumor cells and are capable of inducing apoptosis. Also provided are superantigen-glycolipid conjugates and vesicles that are loaded onto antigen presenting cells to activate both T cells and NKT cells. Cell-based vaccines comprise tumor cells engineered to express a superantigen along with glycolipids products which, when expressed, render the cells capable of eliciting an effective anti-tumor immune response in a mammal into which these cells are introduced. Included among these compositions are tumor cells, hybrid cells of tumor cells and accessory cells, preferably dendritic cells. Also provided are T cells and NKT cells activated by the above compositions that can be administered for adoptive immunotherapy. | 03-10-2011 |
| 20110059900 | Diagnosing and treating hormone resistant cancers - Provided herein are methods and compositions related to diagnosing and treating hormone resistant cancers. | 03-10-2011 |
| 20110059899 | Kruppel-like factor 6 (KLF6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein - The present invention relates to identification of tumor suppressor activity of a protein, KLF6 (KLF6), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation or alteration. | 03-10-2011 |
| 20110059898 | PRO-OXIDANT ANTI-CANCER COMPOUNDS - This invention relates to anti-cancer compounds and to methods for treating or preventing cancer. In particular, the invention concerns pro-oxidant anti-cancer compounds, such as pro-oxidant forms of vitamin E, that selectively interact with complex II of the mitochondrial respiratory chain of cancerous cells, generate reactive oxygen species and induce apoptosis of those cells. | 03-10-2011 |
| 20130165390 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 06-27-2013 |
| 20160089416 | METHOD OF TREATING CANCER - This disclosure pertains to a method of treating liver cancer using a peptide based on venom from a | 03-31-2016 |
| 20110021441 | CONJUGATE COMPRISING P21 PROTEIN FOR THE TREATMENT OF CANCER - The P21 protein is used as a medicament in the treatment of cancer. A conjugate comprises a first region comprising the P21 protein, or a homologue or functional fragment thereof; and a second region comprising a translocation factor. | 01-27-2011 |
| 20150141346 | COMPOSITIONS INCLUDING TRICIRIBINE AND BORTEZOMIB AND DERIVATIVES THEREOF AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 05-21-2015 |
| 20110098233 | HLA-A* 1101-RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention relates to an HLA-A*1101-restricted WT1 peptide, specifically, a peptide comprising an amino acid sequence consisting of 9 contiguous amino acids from a | 04-28-2011 |
| 20110105409 | Anticancer Compounds - Anticancer compounds of general formula I: | 05-05-2011 |
| 20110105408 | THERAPEUTIC PEPTIDES - The invention relates to dendrimer agents presenting polypetides providing the binding domain of a β integrin sub-unit for an ERK MAP kinase, or a variant or modified form of the binding domain, and the use of the dendrimers to inhibit growth of cancer cells. The peptides present more that 8 units of the polypeptide(s) examples of which include the peptide RSKAKNPLYR (SEQ ID No. 6). | 05-05-2011 |
| 20150111832 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS - This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics. | 04-23-2015 |
| 20140073584 | Thienopyranones as Kinase Inhibitors - The invention relates to compounds of formula I (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including inhibition of kinase activity such as PI-3 kinase. | 03-13-2014 |
| 20140073580 | COMBINATIONS OF HDAC INHIBITORS AND PROTEASOME INHIBITORS - Provided herein are pharmaceutical agents, pharmaceutical compositions, methods of treatment, treatment regimens and kits for the treatment of cancer. | 03-13-2014 |
| 20100286058 | Assessing Chemotherapy Resistance of Colorectal Tumors by Determining Sparc Hypermethylation - Hypermethylation of the SPARC promoter is identified as a mechanism for repressing SPARC gene in cancer resulting in resistance to therapy. The restoration of SPARC expression with demethylating agents, such as 5-Aza-2′deoxycytidine, is shown to enhance chemosensitivity. The invention provides a mechanism of limiting the number of patients exposed to toxicity of demethylating agents by targeting its administration to the subset of patients with hypermethylation of the SPARC promoter. | 11-11-2010 |
| 20110130340 | METHODS OF IDENTIFYING ANTI-CANCER AGENTS AND USES THEREOF - The present invention provides methods of identifying and/or detecting anti-cancer agents. The present invention provides methods of identifying and/or detecting compounds that can activate PARP and/or induce necrosis. The present invention also provides for methods of treating cancer in an individual. The present invention also provides kits for identifying and/or detecting anti-cancer agents. | 06-02-2011 |
| 20120184494 | MULTIPLE MYELOMA PROGNOSIS AND TREATMENT - Disclosed herein are diagnostic and prognostic methods for determining the overall survival, and therapeutic regimes, for multiple myeloma patients. The methods involve the detection of PTHR1 gene expression alone or in combination with other clinical factors. The tests are suitable for diagnosing and monitoring treatment of patients having or suspected of having multiple myeloma. The disclosure also relates to proteasome inhibitors and other activators of PTHR1, for the treatment of multiple myeloma. | 07-19-2012 |
| 20100249038 | ANTAGONISTS OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) - Novel peptides are useful as antagonists of RAGE and may be used to treat cancer, inflammation, diabetes and arthritis through the administration of a therapeutically effective amount of the peptide to a subject in need thereof. | 09-30-2010 |
| 20100279950 | PEPTIDES OF A MELANOMA ANTIGEN AND THEIR USE IN DIAGNOSTIC, PROPHYLACTIC, AND THERAPEUTIC METHODS - Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma. | 11-04-2010 |
| 20100298232 | Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof - The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in combination with other inflammatory mediators, are provided. Methods of treatment, alleviation, or prevention of TNF-mediated diseases and inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel diseases, Chrohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, are provided. | 11-25-2010 |
| 20160068582 | CONJUGATE COMPRISING P21 PROTEIN FOR THE TREATMENT OF CANCER - The P21 protein is used as a medicament in the treatment of cancer, conjugate comprises a first region comprising the P21 protein, or a homologue functional fragment thereof; and a second region comprising a translocation factor. | 03-10-2016 |
| 20110112036 | PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGS OR PACLITAXEL CONJUGATES AND RELATED METHODS OF PREPARATION AND USE - Pharmaceutical compositions useful for hydrophobic agents paclitaxel, paclitaxel analogs and conjugates thereof (e g ANG1005) which do not contain Cremophor™ The compositions further comprise an optional tonicity agent, a buffering agent a bulking agent and a solubilizmg agent which is not Cremophor™ Methods of preparing said compositions and of said compositions in the treatment of cancer are also included. | 05-12-2011 |
| 20150080316 | FUNCTIONALIZED THIENO-INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER - The invention relates to new functionalized thieno-indole derivatives of formula (I) or (II) which have cytotoxic activity and are useful in treating diseases such as cancer and cellular proliferation disorders. The invention also relates to the use of these functionalized thieno-indole derivatives in the preparation of conjugates. Formula (I) or (II) wherein R | 03-19-2015 |
| 20110130343 | IMMUNITY-INDUCING AGENT AND METHOD FOR DETECTION OF CANCER - An immunity-inducing agent comprising as an effective ingredient(s) at least one polypeptide selected from the following polypeptides, the polypeptide(s) having an immunity-inducing activity/activities, or as an effective ingredient(s) a recombinant vector(s) which comprise(s) a polynucleotide(s) encoding the polypeptide(s) and is/are capable of expressing the polypeptide(s) in vivo can be used for therapy and/or prophylaxis of cancer: (a) a polypeptide consisting essentially of not less than 7 consecutive amino acids in any one of the amino acid sequences shown in the odd number IDs of SEQ ID NOs:3 to 95 in SEQUENCE LISTING; (b) a polypeptide having a sequence identity of not less than 90% with the polypeptide (a) and consisting essentially of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof. Further, since the above polypeptide(s) react(s) with antibodies existing specifically in serum of a cancer patient, it is possible to detect cancer in a living body by measuring the antibodies in a sample. | 06-02-2011 |
| 20130338081 | IAP ANTAGONISTS - There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. | 12-19-2013 |
| 20100298233 | COMPOSITIONS AND METHODS RELATED TO PROFILING A PLURALITY OF CELLS BASED ON PEPTIDE BINDING - Methods and compositions are described for classifying cells and/or peptides that associate or bind with a particular characteristic pattern to a plurality of cells or cell lines. Aspects of the invention also include the use of peptide(s) having an appropriate binding characteristic to deliver a drug to a cell or cell population. | 11-25-2010 |
| 20130184222 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE - Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here. | 07-18-2013 |
| 20150105327 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VprBP-RELATED CANCERS - This disclosure provides methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity. Also provided are methods of determining the effectiveness of the methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity, methods for detecting a cancer, and methods for screening potential agents that inhibit VprBP kinase activity. | 04-16-2015 |
| 20160113911 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - The methods and uses described herein relate to the role of KDM4A in, e.g. cancer, and permit, e.g. the diagnosis, prognosis, and treatment of cancer and graft vs. host disease. | 04-28-2016 |
| 20140179619 | POLYPEPTIDE, NUCLEOTIDE SEQUENCE THEREOF, AND METHOD FOR USING THE SAME FOR PREVENTING DNA SYNTHESIS AND INHIBITING CELL PROLIFERATION - A polypeptide represented by SEQ. ID.NO. 1. And a method for treatment of a tumor and another disease associated with abnormal cell proliferation, the method including administering a pharmaceutically-effective amount of the polypeptide to a patient in need thereof. | 06-26-2014 |
| 20100292164 | DIMERIZED PEPTIDE - The present invention provides a novel tumor antigen peptide and its cancer vaccine, specifically, a peptide dimer wherein two peptide monomers consisting of 7-30 amino acids including at least one cysteine residue and being capable of producing a tumor antigen peptide are bound each other through a disulfide bond. | 11-18-2010 |
| 20110212898 | CHIMERIC PEPTIDES FOR THE REGULATION OF GTPASES - Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene. | 09-01-2011 |
| 20100292162 | SOCS-3 PROMOTER METHYLATION IN CANCER - This invention provides compositions and methods for the diagnosis and treatment of cancers that exhibit decreased SOCS-3 expression. | 11-18-2010 |
| 20100305041 | CELL PERMEABLE P18 RECOMBINANT PROTEINS, POLYNUCLEOTIDES ENCODING THE SAME, AND ANTICANCER COMPOSITION COMPRISING THE SAME - The present invention discloses cell permeable p18 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a tumor suppressor p18. Also disclosed are polynucleotides encoding the cell permeable p18 recombinant proteins, an expression vector containing the cell permeable p18 recombinant protein, and a pharmaceutical composition for treating p18 deficiency or failure which contains the cell permeable p18 recombinant protein as an effective ingredient. The cell permeable p18 recombinant proteins of the present invention are capable of efficiently introducing a haploinsufficient tumor suppressor p18 into a cell, and thus, can activate cell signaling mechanisms involved in the activation of ATM and p53 that induce cell cycle arrest and apoptosis in response to DNA damage or oncogenic signals. Therefore, the cell permeable p18 recombinant proteins of the present invention can be effectively used as an anticancer agent. | 12-02-2010 |
| 20160115212 | TUMOR-ASSOCIATED PEPTIDES BINDING PROMISCUOUSLY TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS II MOLECULES - The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 04-28-2016 |
| 20120302510 | HISTONE DEACETYLASES, AND USES RELATED THERETO - The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell proliferation and differentiation in vitro and in vivo. | 11-29-2012 |
| 20110195911 | SYNTHETIC ANALOGS OF THE JUXTAMEMBRANE DOMAIN OF IGF1R AND USES THEREOF - A peptide or peptidomimetic comprising the amino acid sequence RXGNGV (SEQ ID NO: 1) or the inverse thereof, or comprising at least six contiguous amino acids of the juxtamembrane domain of IGF1R (SEQ ID NO: 43) or inverse thereof, wherein the peptide or peptidomimetic comprises a total of about 50 or fewer amino acids and inhibits IFG-R1 activity, as well as a method of inhibiting a IGF1R in a cell, a method of treating or preventing IGF1R-mediated disease, and related compounds, compositions, and methods. | 08-11-2011 |
| 20110195910 | USE OF TOCOTRIENOL COMPOSITION FOR THE PREVENTION OF CANCER - The present invention is directed to a method of preventing cancer or preventing the recurrence of cancer after undergoing a cancer treatment by administering a composition comprising at least one of γ-tocotrienol or δ-tocotrienol, wherein the cancer is selected from the group consisting of melanoma, prostate cancer, prostate intraepithelial neoplasia, colon cancer, liver cancer, bladder cancer, breast cancer and lung cancer. The present invention is further directed to a composition comprising at least one of γ-tocotrienol or δ-tocotrienol and Docetaxel and/or Dacarbazine, and to a method of inhibiting or arresting or reversing of cancer by administering a composition comprising at least one of γ-tocotrienol or δ-tocotrienol together with Docetaxel and/or Dacarbazine. The present invention is also directed to methods of manufacturing those compositions. | 08-11-2011 |
| 20110263512 | CONJUGATES FOR THE TREATMENT OF MESOTHELIOMA - The present invention provides conjugates of cytokines and targeting peptides that is able to bind to a receptor expressed on tumor-associated vessels or to a component of the extracellular matrix associated to the tumor vessels, for treatment of malignant pleural mesothelioma. In particular, the invention provides conjugates comprising the cytokine TNF linked to a peptide containing the NGR motif. The invention further provides pharmaceutical compositions comprising such conjugate and pharmaceutical formulations comprising conjugates dissolved in appropriate buffers. | 10-27-2011 |
| 20130331333 | PAR1 AND PAR2 C-TAIL PEPTIDES AND PEPTIDE MIMETICS - The present invention concerns isolated PAR1 cytoplasmic tail (c-tail) peptides and isolated PAR2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer. | 12-12-2013 |
| 20150328278 | METHOD FOR ACTIVATING HELPER T CELL - The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to an MHC class II molecule selected from HLA-DRB1*08:02 molecule, an HLA-DRB1*13:02 molecule, an HLA-DRB1*14:03 molecule, an HLA-DRB1*14:05 molecule, an HLA-DQB1*03:02 molecule, and an HLA-DQB1*04:01 molecule. | 11-19-2015 |
| 20110082089 | BIOMARKERS FOR MONITORING OR PREDICTING THE TREATMENT OF CANCER - We provide for the diagnosis, prognosis and/or treatment monitoring of lung cancer or bronchial dysplasia, and the use thereof for predicting and monitoring therapeutic intervention in dysplasia or cancer patients. According to the invention at least one biomarker selected from the group consisting of APOE, APOC3, A1AT6, A2MG, PROP, TTHY, A1AG8, APOA1, APOH, GPX3, MUP8, RETBP, SAMP, VTDB, S6A11, EGFR, ApoA4, ApoM, a-raf, fetuin B, GSN, PLG, VPS28, and particular peptide sequences derived thereof, is used in the diagnosis, prognosis and/or treatment monitoring of cancer or dysplasia, in particular of lung cancer or the level of at least one of said biomarkers is measured in a body fluid sample, in particular in a blood serum sample, of a patient suffering from or being susceptible to cancer or dysplasia. | 04-07-2011 |
| 20140349945 | PEG-AMINO ACID-OLIGOPEPTIDE-IRINOTECAN DRUG CONJUGATES AND THE PHARMACEUTICAL COMPOSITIONS - A PEG-oligopeptide-irinotecan conjugate has the general formula (I) (shown below) and a pharmaceutical composition containing the conjugate are disclosed. In the conjugate, PEG represents polyethylene glycol with a molecular weight of 300-60,000 Daltons; (AA) | 11-27-2014 |
| 20120309691 | TUMOR TARGETED DELIVERY OF IMMUNOMODULATORS BY NANOPOLYMERS - Nanoconstructs having three components: (1) biodegradable nanopolymers and nanoparticles, (2) immunodrugs such as CpG, and a (3) tumor binding device, which are actively targeted to tumor cells such as melanoma cells through receptor-mediated uptake and methods of using the same are described. Antitumor immunity is further enhanced by combination of PG-CpG nanoconstructs with agonists of positive costimulatory signals and inhibitors of negative immune regulatory signals. | 12-06-2012 |
| 20120309690 | PROSTAGLANDIN-F2 ALPHA RECEPTOR MODULATORS AND USES THEREOF - Prostaglandin-F2 alpha (PGF2α) receptor (FP) modulators of formula I, as well as the use of PGF2α receptor modulators for the treatment of conditions associated with FP activity such as preterm labor and colorectal cancer, are disclosed. | 12-06-2012 |
| 20130338080 | COMPOSITIONS AND METHODS FOR TREATING AN ACTIVATED B-CELL DIFFUSE LARGE B-CELL LYMPHOMA - The invention relates to compositions and methods for treating an activated B-Cell Diffuse Large B-Cell Lymphoma (ABC-DLBCL). Specifically, the invention relates to treating ABC-DLBCL by administering an NF-κB Essential Modulator (NEMO) Binding Domain (NBD) peptide or a mimetic thereof that inhibits NF-κB activation. | 12-19-2013 |
| 20140194366 | OVARIAN CANCER STEM CELLS AND METHODS OF ISOLATION AND USES THEREOF - The present invention generally relates to methods, assays, compositions and kits related to a subpopulation of ovarian cancer stem cells which are selected or enriched by chemotherapeutic agents and inhibited by MIS (Mullerian Inhibiting Substance) and MIS mimetics. In particular, the present invention relates to a population of CD44+/CD24+/EpCam+/ECad− subpopulation of ovarian cancer stem cells. The present invention also provides methods to screen a subject with ovarian cancer to identify if they have an ovarian cancer comprising CD44+/CD24+/EpCam+/ECad− ovarian cancer stem cells, and methods to identify and enrich or isolate for such ovarian cancer cell populations. | 07-10-2014 |
| 20130109628 | MICRORNA COMPOSITIONS AND METHODS RELATED THERETO | 05-02-2013 |
| 20140315825 | ANTI-CANCER COMPOSITIONS CONTAINING WNT DECOY RECEPTOR - The present invention relates to a composition for preventing or treating cancer comprising Wnt decoy receptor. The composition of the present invention or the expression product thereof inhibits cancer generation, growth, proliferation and metastasis, and induces apoptosis of cancer cells, by binding to Wnt ligand and blocking ligand-receptor interactions, therefore may be effectively used as an anti-cancer agent. | 10-23-2014 |
| 20120252737 | Methods for Diagnosing and Treating Cancer - The invention provides methods for decreasing one or more symptoms of cancer in a patient requiring the steps of determining the activation or inactivation of the MK2 signaling pathway and, based on these determinations, administering either a MK2 inhibitor or a combination of a MK2 inhibitor and a chemotherapeutic agent, or a chemotherapeutic agent to the patient. The invention further provides methods for identifying a cancer patient that may selectively benefit from the administration of a chemotherapeutic agent, or the administration of a MK2 inhibitor or the combination of a MK2 inhibitor and a chemotherapeutic agent, requiring the steps of determining the activation or inactivation of the MK2 signaling pathway. The invention additionally provides methods and kits for diagnosing a chemotherapy-sensitive or chemotherapy-resistant cancer in a subject that require the step of (or reagents for) determining the activation or inactivation of the MK2 signaling pathway. The invention also provides methods of treating a cancer patient diagnosed as having a chemotherapy-sensitive or a chemotherapy-resistant cancer. | 10-04-2012 |
| 20130338079 | TREATMENT OF PRIMARY AND METASTATIC CARCINOMA - Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ET | 12-19-2013 |
| 20120021993 | PROTEIN SCAFFOLD LIBRARY BASED ON KRINGLE DOMAIN STRUCTURE AND USES THEREOF - There are provided a Kringle domain structure, comprising: inducing artificial mutations at amino acid residues except for conserved amino acid residues that are important to maintain the structural scaffold of a Kringle domain; and protein scaffold variants, based on the Kringle domain structure, which modulate the biological activities of a variety of target molecules derived from the protein scaffold library by specifically binding to the target molecules. Also, there is provided a method for constructing homo-/hetero-oligomers which allow multi-specificity binding to multiple targets by the tandem assembly monomeric Kringle domain variants using a linker. Additionally, there is provided a method for preparing multispecific monomers and multivalent monomers by grafting target-binding loops of a Kringle domain variant into non-binding loops of another Kringle domain variant with the same or different target binding specificity. Furthermore, a protein scaffold variant based on the Kringle domain structure that specifically binds to target molecules, DNA encoding the protein scaffold variant, or a method and composition for prevention, detection, diagnosis, treatment or relieving diseases or disorders, particularly cancers and other immune-related diseases, comprising: administering an effective amount of the related molecule to animals, preferably human. | 01-26-2012 |
| 20140018301 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 01-16-2014 |
| 20110118191 | Crotoxin Administration for Cancer Treatment and Pain Relief - Disclosed is a method for treating cancer and/or pain using an intra-patient dose escalation procedure to deliver dosages of crotoxin. | 05-19-2011 |
| 20130345143 | MODULATION OF p62 FUNCTION THROUGH THE PB1 DOMAIN - Provided are methods, compositions, and kits employing a molecule that exhibits a function of the PB | 12-26-2013 |
| 20140357573 | PROGNOSTIC ASSAY FOR SQUAMOUS CELL LUNG CARCINOMA - Methods for predicting clinical outcome for a human subject diagnosed with squamous cell lung carcinoma using a panel of molecular markers that includes CDKN2A and CCND1. The markers are related to the subject's increased likelihood of a negative clinical outcome. | 12-04-2014 |
| 20120252739 | Tubulin Inhibitors - The present invention relates to novel tubulin binding molecules of formula (I) and their use for the treatment of cancer and other diseases. | 10-04-2012 |
| 20120157390 | IAP Inhibitors - Smac mimetics that inhibit IAPs. | 06-21-2012 |
| 20140038900 | DOMINANT NEGATIVE HSP110 MUTANT AND ITS USE IN PROGNOSING AND TREATING CANCERS - The present invention relates to a mutated heat-shock protein 110 (HSP110) lacking its substrate binding domain, which does not exhibit its chaperone activity and/or is not capable of binding to heat-shock protein 70 (HSP70) and/or to heat-shock protein 27 (HSP27), but which is capable of binding to a wild-type HSP 110. Such a mutated heat-shock protein 110 can be used (i) in methods for prognosing survival and/or the response to a treatment of a patient suffering from a cancer, more particularly from a cancer liable to have a microsatellite instability (MSI) phenotype, such as colorectal cancer (CRC), and (ii) for treating cancers. | 02-06-2014 |
| 20110183917 | P53 Activator Peptides - The present invention relates to novel polypeptides that activate p53, and the polynucleotides encoding these p53 activator peptides. The present invention also relates to pharmaceutical compositions comprising the p53 activator peptides as well as methods of treating abnormal conditions, such as malignant tumors, with the methods comprising administering the pharmaceutical compositions of the present invention to a subject in need of treatment thereof. | 07-28-2011 |
| 20140256646 | MULTI-LEU PEPTIDES AND ANALOGUES THEREOF AS SELECTIVE PACE4 INHIBITORS AND EFFECTIVE ANTIPROLIFERATIVE AGENTS - Disclosed herein are PACE4 inhibitors, compositions comprising PACE4 inhibitors and their uses thereof for lowering PACE4 activity, reducing cell proliferation, reducing tumor growth, reducing metastasis formation, preventing and/or treating cancer. Also provided are methods for lowering PACE4 activity, reducing the proliferation of a cell, reducing tumor growth and/or treating and preventing cancer. Methods for screening PACE4 inhibitors and cell proliferation inhibitors are further provided. | 09-11-2014 |
| 20120172312 | MUC-1 CYTOPLASMIC DOMAIN PEPTIDES AS INHIBITORS OF CANCER - The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo. | 07-05-2012 |
| 20140066383 | METHODS OF TREATING CANCER - Described are methods and compositions for treating epithelial tumors with a folate-vinca conjugate in combination with at least one other chemotherapeutic agent in which the tumors include ovarian, endometrial or non-small cell lung cancer tumors, including platinum-resistant ovarian tumors and platinum-sensitive ovarian tumors. | 03-06-2014 |
| 20130005664 | THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 01-03-2013 |
| 20100292161 | POLYPEPTIDES AND METHODS OF USE - Described herein are fragments of fibronectin and vitronectin and variants thereof that have certain activities, including growth factor-binding activity. Also described are fragments of growth factors that bind to fibronectin and inhibit binding of full-length growth factors to fibronectin. Compositions containing such fragments are useful in cosmetic treatments (e.g., the treatment of wrinkles or UV photodamage of skin), and the treatment of wounds and cancer. | 11-18-2010 |
| 20100292160 | HLA-A* 3303-RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and others. | 11-18-2010 |
| 20140038899 | BIOMARKERS FOR OVARIAN CANCER - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer, ovarian cancer of low malignant potential, benign ovarian disease or other malignant condition. The biomarkers can be detected by SELDI mass spectrometry. | 02-06-2014 |
| 20140364375 | Combination Therapy with Peptide Epoxyketones - The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent. | 12-11-2014 |
| 20140364374 | AMINO ACID SEQUENCE FOR INHIBITING PTX3 TO TREAT NASOPHARYNGEAL CARCINOMA - The invention relates to an amino acid sequence for inhibiting PTX3 to treat nasopharyngeal carcinoma. It can be used to inhibit PTX3 from promoting the migration and invasion of nasopharyngeal carcinoma cells, promoting angiogenesis and inhibiting macrophage phagocytosis to further treat nasopharyngeal carcinoma. | 12-11-2014 |
| 20130165389 | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN-DRUG CONJUGATES, XTEN-DRUG CONJUGATES AND METHODS OF MAKING AND USING SAME - The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions. | 06-27-2013 |
| 20140296156 | PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER - Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods. | 10-02-2014 |
| 20130196928 | LIBRARY FROM TOXIN MUTANTS AND METHODS OF USING SAME - This application relates to ABx toxin mutants and libraries of said mutant proteins, in which a peptide insert is introduced into the protease-sensitive loop of the A-chain sequence to alter the type of cells to which toxic species are delivered. Said libraries are used in the development of therapeutics targeted against specific cell types. | 08-01-2013 |
| 20140213528 | Fibrosuppressant Biotherapeutics - The invention relates to IHG-1 (induced by high glucose-1) a novel gene which encodes a protein that amplifies fibrotic responses in in vitro and in vivo models of fibrotic disorders and in human diabetic nephropathy. In particular the invention relates to modifications of the IHG-1 structure which are potential fibrosuppressant biotherapeutics and modify cellular invasiveness. The invention also relates to a method of screening a therapeutic agent for suitability for the treatment of fibrotic disease comprising testing a candidate therapeutic agent for the ability to reduce the expression of IHG-1 levels in a model system. | 07-31-2014 |
| 20140213527 | SMALL HUMANIN-LIKE PEPTIDES - Novel peptides referred to as small humanin-like peptides (SHLPs) are provided herein along with nucleic acids encoding SHLPs and probes that selectively bind SHLPs. SHLPs have wide-ranging activity, including neuroprotective activity, anticancer activity, and cell survival activity. Also provided herein are therapeutic methods comprising administering an effective amount of an SHLP to a subject in need of treatment. | 07-31-2014 |
| 20110046070 | GENE EXPRESSION INHIBITOR SELECTIVE FOR MATRIX METALLOPROTEINASE-9 GENE - Disclosed are: an inhibitor of the expression of matrix metalloproteinase-9 gene; a therapeutic agent for a disease associated with matrix metalloproteinase-9; and a carcinostatic agent. Each of the agents comprises a pyrrole-imidazole polyamide having an N-methylpyrrole unit, an N-methylimidazole unit and a γ-aminobutyric acid unit. The pyrrole-imidazole polyamide can be folded at the site of the γ-aminobutyric acid unit to form a U-shaped conformation in a minor groove of a double-stranded domain comprising a part or the whole of a specific nucleotide sequence (SEQ ID NO:2, SEQ ID NO:4) included in a human matrix metalloproteinase-9 gene promoter and a strand complementary to the part or the whole of the specific nucleotide sequence. In the U-shaped conformation, a Py-Im pair, an Im/Py pair and a Py/Py pair in the pyrrole-imidazole polyamide target a C-G base pair, a G-C base pair, and both of an A-T base pair and a T-A base pair in the minor groove, respectively. | 02-24-2011 |
| 20130165391 | B2-GLYCOPROTEIN I PEPTIDE INHIBITORS - Therapeutic peptides (and peptoids) for preventing or inhibiting tissue damage associated with ischemia and/or reperfusion are provided, along with peptides (and peptoids) for preventing or inhibiting cancerous tissue growth. The peptides are derived from β2-glycoprotein I. Pharmaceutical and veterinary compositions comprising the peptides are also provided. Methods of using the peptides to prevent or inhibit tissue damage associated with ischemia and/or reperfusion and/or to prevent or inhibit tissue damage or the growth of cancerous tissue are also provided. | 06-27-2013 |
| 20130184221 | Kinase Inhibitors And Uses Thereof - The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population. | 07-18-2013 |
| 20160122415 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer. | 05-05-2016 |
| 20140235549 | STABILIZED POLYPEPTIDES AS REGULATORS OF RAB GTPASE FUNCTION - The present invention provides inventive polypeptides comprising a C terminal RAB binding domain (RabBD) of RAB family interacting proteins (FIPs) stabilized by peptide stapling, and pharmaceutical compositions thereof. Also provided are methods for modulating RAB function comprising contacting an inventive stapled polypeptide with a RAB protein, and methods of treatment associated with modulation of RAB activity. The present invention also provides methods of making the inventive stapled polypeptides by ring closing metathesis of unstapled polypeptide precursors. | 08-21-2014 |
| 20130261064 | N-CARBOXYALKYL-AURISTATIN AND THE USE THEREOF - The present application relates to new derivatives of monomethylauristatin F, substituted on the N terminus by a carboxyalkyl group, processes for preparing these derivatives, their use for the treatment and/or prevention of diseases and to produce medication for the treatment and/or prevention of diseases, particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments can occur as monotherapies or in combination with other medication or further therapeutic measures. | 10-03-2013 |
| 20150111831 | METHOD FOR TREATING GLIOMA USING TARBP2 - A pharmaceutical composition and a method for treating glioma are provided. The pharmaceutical composition for preventing or treating glioma includes a Tar RNA binding protein 2 (Tarbp2) protein or gene encoding the same as an active component. The method for treating glioma includes administering to a subject in need thereof a pharmaceutically effective amount of aTar RNA binding protein 2 (Tarbp2) protein or gene encoding the same. | 04-23-2015 |
| 20140329759 | POLYETHYLENE GLYCOL-MODIFIED INTEGRIN BLOCKER HM-3 AND USE THEREOF - The present invention involves the pharmaceutical field, including integrin antagonists, which have the capacities of inhibiting angiogenesis of tumors, binding integrin. These antagonists are a kind of polypeptide, which was modified by polyethylene glycol and after modification, it can be used to treat tumors. The sequence and structure of these antagonists is mPEG-SC | 11-06-2014 |
| 20150344534 | OSTEOPONTIN VARIANTS FOR USE IN SUPPRESSION OR PREVENTION OF TUMOR GROWTH AND COMPOSITIONS CONTAINING SUCH OSTEOPONTIN VARIANTS - The present invention relates to pharmaceutical compositions and nutritional supplements comprising an osteopontin variant, and medical use of such compositions and supplements for treating or preventing tumor-generating cancer. | 12-03-2015 |
| 20150344526 | BIOLOGICALLY ACTIVE COMPLEX AND ITS PREPARATION - A biologically active complex comprising either a polypeptide having the sequence of a variant of a naturally occurring protein, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein; or a peptide of up to 50 amino acids, for instance a fragment of the naturally occurring protein or a variant thereof; and a pharmaceutically acceptable salt of a fatty acid or lipid. The complexes of the invention demonstrate a novel mode of action, which gives rise to opportunities for the development of further active agents and screening methods. | 12-03-2015 |
| 20130217635 | NOVEL USE OF ERYTHROID DIFFERENTIATION REGULATOR 1 AS AN AGENT FOR TREATING CANCER - The present invention relates to a novel use of erythroid differentiation regulator 1 (Erdr1) as an agent for treating cancer. More particularly, it relates to an use of Erdr1 or an expression vector including a polynucleotide encoding the same for preventing and inhibiting cancer metastasis, an use of Erdr1 or an expression vector including a polynucleotide encoding the same for preventing and treating cancer, an use of an antibody specific for Erdr1 for diagnosing cancer, or a method for screening agents for regulating cancer metastasis or cancer cells migration. The Erdr1 is negatively regulated by IL-18 expression and it suppresses migration, invasion and metastasis of cancer or tumor cell by expression of HSP90 and generation of ROI. And an Erdr1 recombinant protein promotes NK-cell killing activity against cancer cell. Accordingly, the Erdr1 and an expression vector comprising polynucleotide encoding the same and recombinant protein suppress cancer metastasis and bring an effect on activation of immune cells, and therefore can be useful for preventing, treating and diagnosing cancer. | 08-22-2013 |
| 20150344442 | CYCLIC AMINES AS BROMODOMAIN INHIBITORS - The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy. | 12-03-2015 |
| 20150344523 | MUTANT AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING - The present application provides stable peptide-based Akt capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing Akt capture agents using iterative on-bead in situ click chemistry. | 12-03-2015 |
| 20120329725 | Chimeric Peptides for the Regulation of GTPases - Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene. | 12-27-2012 |
| 20110245185 | APO-2 ligand/trail formulations - The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as well as devices and kits containing such formulations are also provided. | 10-06-2011 |
| 20140315824 | PEPTIDE PREPARATIONS AND PEPTIDES WITH ANTITUMOUR ACTIVITY - The subject of the present invention are peptide preparations obtained via the enzymatic digestion of hair, wool, bristles, animal fur and individual peptides with sequences corresponding to individual components of a peptide preparation with antitumour activity, for use in the treatment of tumours or oncological prophylaxis as basal components or components of compositions of substances for treating tumours or components of substances used in oncological prophylaxis. | 10-23-2014 |
| 20130210744 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST - Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid and/or derivative thereof; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anticancer-associated fibroblast composition; and a method for treatment of cancer. | 08-15-2013 |
| 20130210743 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 08-15-2013 |
| 20120101045 | TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS - The disclosure provides fusion polypeptides and constructs useful in delivering anionically charged nucleic acid molecules including diagnostics and therapeutics to a cell or subject. The fusion constructs include a protein transduction domain and a nucleic acid binding domain, or a protein transduction domain and a nucleic acid that is coated with one or more nucleic acid binding domains sufficient to neutralize an anionic charge on the nucleic acid. Also provided are methods of treating disease and disorders such as cell proliferative disorders. | 04-26-2012 |
| 20130178428 | LONG NONCODING RNA (LNCRNA) AS A BIOMARKER AND THERAPEUTIC MARKER IN CANCER - Long noncoding RNAs (lncRNAs) that may be used as cancer biomarkers and methods of diagnosing, prognosing and monitoring cancer including, but not limited to, cutaneous melanoma using said lncRNAs are provided herein. In some embodiments, the methods include steps of isolating one or more lncRNA transcripts in a biological sample from the subject; measuring a test level of the one or more isolated lncRNA transcripts; comparing the test level to a control level of the one or more lncRNA transcripts; and diagnosing or making a prognosis based on the lncRNA level. In some embodiments, the lncRNA transcript is an linc00340 transcript or variant thereof. These lncRNA transcripts may also be used as a therapeutic target in the treatment of cancer. | 07-11-2013 |
| 20140256648 | HJURP PEPTIDES AND VACCINES INCLUDING THE SAME - Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding the peptides as well as pharmaceutical agents, substances and/or compositions that include any of the peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find utility in the treatment of cancers, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor. | 09-11-2014 |
| 20140256649 | PROTEIN-PROTEIN INTERACTION AS BIOMARKERS - The subject invention pertains to materials and methods for the classification of cancers as sensitive or resistant to treatments based on protein-protein interactions, treatment of cancer, identification of biomarkers, identification of protein-protein interaction modulators, and selection of cancer treatments. | 09-11-2014 |
| 20140371157 | METHODS OF DOWNREGULATING TRANSLOCATED ONCOGENE EXPRESSION USING BROMODOMAIN INHIBITORS - Disclosed herein are novel methods and compositions useful for inhibiting interaction between a bromodomain protein and an immunoglobulin (Ig) regulatory element. The methods and compositions are particularly useful for downregulating expression of an oncogene translocated with an Ig locus, as well as for treating a cancer (e.g., hematological malignancy) characterized by increased expression of an oncogene which is translocated with an Ig locus. Also disclosed herein are methods and assays for identifying agents that interfere with binding of bromodomain proteins to Ig regulatory elements, as well as methods and assays for identifying inhibitors of bromodomain | 12-18-2014 |
| 20140011746 | SYNDECAN PEPTIDES AND POLYPEPTIDES AS INHIBITORS OF CANCER - The invention provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit α4β6 interaction with HER2, thereby preventing tumor cell growth and tissue invasion. | 01-09-2014 |
| 20100311669 | COMPOUNDS THAT BIND TO P185 AND METHODS OF USING THE SAME - Novel peptides and pharmaceutical compositions comprising the same are disclosed. Conjugated compositions peptides linked to detectable agents and/or cytotoxic agents. are disclosed. Method of detecting tumors that have p185 on tumor cell surfaces are disclosed. Methods of preventing transformation of a normal cell into a tumor cell in an individual at risk of developing a tumor having tumor cells which have p185 on their surfaces are disclosed. Methods of treating an individual who has cancer characterized by tumor cells that have a p185 on their cell surfaces are disclosed. | 12-09-2010 |
| 20150080315 | SALL4 And Uses Thereof - The invention is directed to methods of treating a solid tumor which expresses SALL4 and Phosphatase and Tensin Homolog (PTEN) in an individual in need thereof, comprising administering to the individual an effective amount of a composition that inhibits SALL4. In addition, the invention is directed methods of method of detecting an aggressive cancer in an individual in need thereof comprising detecting whether one or more cancer cells of the individual expresses SALL4, wherein if SALL4 is detected in the one or more cancer cells, then an aggressive cancer is detected in the individual, and methods of method of detecting a poor prognosis of a patient with cancer in an individual in need thereof, comprising detecting whether one or more cancer cells of the patient expresses SALL4, wherein if SALL4 is detected in the one or more cancer cells of the patient, then a poor prognosis is detected in the patient. | 03-19-2015 |
| 20120157389 | PEPTIDES FOR TREATING CANCER - The present invention relates to peptide from 4 to 50 amino acids comprising a phosphorylated pYX | 06-21-2012 |
| 20110312897 | CATHEPSIN L PROTEOLYTICALLY PROCESSES HISTONE H3 DURING MOUSE EMBRYONIC STEM CELL DIFFERENTIATION - Methods and agents useful for modulating histone proteolysis, stem cell differentiation, and gene transcription and for treating cancer are disclosed. Antibodies or antigen binding fragments that selectively bind to histone-3 cleavage products and are useful for diagnosing cancer and monitoring a subject's response to cancer treatment are also disclosed. | 12-22-2011 |
| 20140011748 | Methods Of Predicting Response To JNK Inhibitor Therapy - This present invention provides methods of treating of accessing/monitoring the responsiveness of a cancer cell to JNK inhibitor therapy. | 01-09-2014 |
| 20130059793 | EGF RECEPTOR MIMICKING PEPTIDES - Provided are peptides which can mimic the epidermal growth factor receptor (EGFR), e.g., by selectively binding TGF-α and/or EGF. In certain embodiments, the peptides are retro-inverted peptides. The peptides may be used as soluble decoys for TGF-α and/or EGF, and anti-cancer properties of peptides are demonstrated both in vitro and in vivo. The peptides may be administered alone or comprised in a fusion construct, imaging construct, and/or a therapeutic construct, e.g., for the treatment of a cancer. | 03-07-2013 |
| 20140011749 | KETOGENIC DIET COMPOSITION FOR THE TREATMENT OF CHEMO THERAPY AND/OR RADIATION THERAPY PATIENTS - The present disclosure provides ketogenic compositions for use in the treatment of a cancer patient undergoing chemotherapy or radiation therapy. | 01-09-2014 |
| 20140011747 | SYNDECAN PEPTIDES AND POLYPEPTIDES AS INHIBITORS OF CANCER - The invention provides for peptides from syndecan 4 and methods of use therefor. These peptides can inhibit α6β4 integrin interaction with EGFR, thereby preventing tumor cell growth and tissue invasion. | 01-09-2014 |
| 20140323411 | Method for De-Differentiating A Cell - The invention relates to a method for de-differentiating a cell, i.e. the induction of a pluripotent phenotype. In vivo de-differentiation is carried out using defined factors such as transcription factors, miRNA, DNA, or proteins. This leads to the formation of pluripotent cells, without teratoma formation. Defined factors may be administered to cells such as liver or muscle cells and are useful in therapy. | 10-30-2014 |
| 20140323410 | USE OF HDL-RELATED MOLECULES TO TREAT AND PREVENT PROINFLAMMATORY CONDITIONS - Molecules and compositions are described for use in the treatment and prevention of pro-inflammatory conditions. HDL-related molecules, including ApoA-I, bovine HDL and HDL mimetics, in particular, are demonstrated to prevent UV-induced cell death and oxidative stress in skin cells and to inhibit tumor growth and development in a variety of cancers. HDL-related molecules can be used as an oral supplement and in other compositions to prevent or treat pro-inflammatory skin conditions and systemic proinflammatory conditions, including Alzheimer's disease and various cancers. | 10-30-2014 |
| 20140256647 | KITS AND METHODS FOR THE TREATMENT OF CANCER USING GLIADIN PEPTIDES - Kits and methods for treating cancer comprising administration of a gliadin peptide to a patient are disclosed herein. A kit according to the invention comprises a pharmaceutical composition comprising a gliadin peptide and instructions for administering the peptide to a patient. The kit may further comprise a pharmaceutical composition comprising at least one chemotherapeutic agent such as a receptor tyrosine kinase inhibitor and instructions for co-administering the compounds. A method of treating cancer according to the invention comprises administering a gliadin peptide to a patient and may further comprise co-administering at least one chemotherapeutic agent such as a receptor tyrosine kinase inhibitor. Co-administration of a gliadin peptide and receptor tyrosine kinase inhibitor to a patient with cancer is effective to decrease or prevent resistance of the cancer to the receptor tyrosine kinase inhibitor. | 09-11-2014 |
| 20130065836 | BIOMARKER FOR GASTRIC CANCER - The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the BCL6B gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing BCL6B gene expression or activity. | 03-14-2013 |
| 20150335702 | Inhibitors of Atypical Protein Kinase C and Their Use in Treating Hedgehog Pathway-Dependent Cancers - Methods and compositions are provided for modulating Hedgehog (Hh) pathway signaling in a cell. Aspects of the methods include methods for inhibiting Hh pathway-promoted cancer proliferation and/or metastasis that is promoted by Hh pathway signaling, methods for treating cancers promoted by Hh pathway signaling, and methods for screening candidate agents for the ability to treat a cancer promoted by Hh pathway signaling. In addition, reagents and kits thereof that find use in practicing the subject methods are provided. | 11-26-2015 |
| 20160046677 | PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES - The invention provides a | 02-18-2016 |
| 20130116195 | Binding ligand linked drug delivery conjugates of tubulysins - Described herein are compounds, pharmaceutical compositions, and methods for treating pathogenic cell populations. Kits including the compounds or pharmaceutical compositions are described. The compounds described herein include conjugates of tubulysins and folates. The conjugates also include a releasable bivalent linker. | 05-09-2013 |
| 20120015888 | T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials. | 01-19-2012 |
| 20140135272 | NOVEL ZINC FINGER-LIKE PEPTIDE COMPOSITIONS AS POTENT AGENTS IN CANCER PREVENTION AND TREATMENT - A zinc finger-like peptide for treating cancer, a pharmaceutical composition containing the zinc finger-like peptide and a method for treating cancer are disclosed. In the present invention, the zinc finger-like peptide for treating cancer comprises: at least seven amino acids, wherein the sequence of the at least seven amino acids has 85-100% similarity to a sequence represented by SEQ ID NO: 1. | 05-15-2014 |
| 20120202750 | INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: | 08-09-2012 |
| 20140005120 | Activity Enhancer for Anticancer Agent | 01-02-2014 |
| 20140005119 | COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS | 01-02-2014 |
| 20130252904 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The invention relates to compounds, compositions, kits, and methods for the treatment of a cancer. In particular, the invention relates to compounds, compositions, or kits comprising a folate-vinca conjugate, and methods for the treatment of a cancer with a folate-vinca conjugate. | 09-26-2013 |
| 20150025018 | METHOD FOR INHIBITING euPTX3 TO TREAT NASOPHARYNGEAL CARCINOMA BY AMINO ACID SEQUENCE - The invention relates to a method for inhibiting euPTX3 to treat nasopharyngeal carcinoma by an amino acid sequence, comprising administering an effective amount of the amino acid sequence to a subject in need. The amino acid sequence can be used to inhibit euPTX3 from promoting the migration and invasion of nasopharyngeal carcinoma cells, promoting angiogenesis and inhibiting macrophage phagocytosis to further treat nasopharyngeal carcinoma. | 01-22-2015 |
| 20140194367 | AGROCYBE AEGERITA LECTIN AAL-2, AND ENCODING GENE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - The isolated | 07-10-2014 |
| 20150072937 | Chimeric Peptides for the Regulation of GTPases - Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene. | 03-12-2015 |
| 20140378389 | T CELL RECEPTORS RECOGNIZING HLA-A1- OR HLA-CW7-RESTRICTED MAGE - The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention. | 12-25-2014 |
| 20160046997 | BIOMARKERS FOR CERVICAL CANCER - The present invention relates to biomarkers for chemoradioresistant subtypes of cervical cancer. In particular the present invention relates to a method for predicting a predisposition to a chemoradioresistant cervical cancer in a subject, a method for diagnosing a chemoradioresistant cervical cancer in a subject, a method for predicting the likelihood of recurrence of cervical cancer in a cervical cancer patient under treatment, and a method for predicting the prognosis for a patient with a chemoradioresistant cervical cancer. | 02-18-2016 |
| 20150353606 | PEPTIDOMIMETIC COMPOUNDS - The present invention relates to inhibitors of protein-protein interactions (PPI). Specifically, the present invention relates to a structural informatics approach to designing peptidomimetic macrocycles containing an amino acid “warhead” for ligand-directed covalent modification of cysteine and lysine-containing proteins for the treatment of diseases such as cancer. Further included is the targeting of components of the BCL2 signaling pathway, specifically BCL2-A1 and MCL-1. | 12-10-2015 |
| 20110053862 | COMPOSITIONS COMPRISING SURVIVIN SIRNA AND METHODS OF USE THEREOF - The present invention provides siRNA nucleic acid molecules that inhibit survivin expression. Methods of using the nucleic acid molecules are also provided. | 03-03-2011 |
| 20110053861 | COMPOSITIONS COMPRISING NUCLEAR FACTOR-KAPPA B (NF-KB) SIRNA AND METHODS OF USE - The present invention provides siRNA nucleic acid molecules that inhibit NF-kappaB expression. Methods of using the nucleic acid molecules are also provided. | 03-03-2011 |
| 20150011478 | CMV GENE PRODUCTS PROMOTE CANCER STEM CELL GROWTH - The disclosure relates generally to compositions and methods useful for inhibiting the infection and propagation of viral particles, particularly members of the Herpesviridae family, and more particularly to cytomegalovirus (CMV) and methods of treating diseases and disorders, including cell proliferative disorders, associated with CMV infection. | 01-08-2015 |
| 20140080763 | N-CARBOXYALKYLAURISTATINS AND USE THEREOF - The present application relates to new derivatives, substituted on the N terminus by a carboxyalkyl group, of monomethylauristatin E and monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and to the use of these derivatives for producing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments may be applied as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 03-20-2014 |
| 20110301094 | NEW TUMOR SUPPRESSOR GENE, P28ING5 - This disclosure provides a novel tumor suppressor, referred to as p28ING5, nucleic acid molecules encoding this protein, and methods of making and using these molecules. Also provided are methods of ameliorating, treating, detecting, prognosing, and diagnosing diseases and conditions associated with abnormal p28ING5 expression, such as neoplasia. Kits are also provided. | 12-08-2011 |
| 20110301093 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER AND NEURODEGENERATIVE DISEASES RELATED TO BECLIN-1 - The present invention relates to antibodies specific for human Beclin-1 protein phosphorylated at position Thr 119 and uses thereof. In particular, these antibodies are useful in diagnosing diseases associated with impaired autophagy including cancer and neurodegenerative diseases. The invention further relates to human Beclin-1 mutated at position 119 with a phospho-mimicking residue and uses thereof for treating cancer and neurodegenerative diseases. | 12-08-2011 |
| 20130296252 | MUC18 TARGETING PEPTIDES - Provided are MUC18 targeting peptides which may be used, e.g., to therapeutically target B-1 lymphocytes to reduce the influence of these cells on the metastatic potential of melanoma cells and/or to target cancerous cells, including certain melanoma and leukemia cells. MUC18 targeting peptides may be comprised in fusion constructs, imaging constructs, and/or therapeutic constructs such as fusion constructs which may be used for diagnosing or treating a cancer. | 11-07-2013 |
| 20160046686 | COMPOSITIONS AND METHODS FOR INHIBITING TUMOR CELLS BY INHIBITING THE TRANSCRIPTION FACTOR ATF5 - The present invention relates to methods for treating and/or preventing tumors and/or promoting apoptosis in a neoplastic cell comprising contacting the neoplastic cell with an cell-penetrating dominant-negative ATF5 (“CP-d/n-ATF5”), wherein the CP-d/n-ATF5 is capable of inhibiting ATF5 function and/or activity. | 02-18-2016 |
| 20160046669 | Method for Inhibiting Proliferation of High Lix1I-Expressing Tumor Cell, and Tumor Cell Proliferation-Inhibiting Peptide - A method is provided for inhibiting proliferation of a high LIX1L-expressing tumor cell, in which the expression or function of a LIX1L gene with respect to a tumor cell highly expressing the LIX1L gene is inhibited. | 02-18-2016 |
| 20130012450 | Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment Of Dermatology Related Genetic Diseases - This invention relates to a transdermal delivery system for treating skin related genetic diseases. More specifically, the present invention provides particles and methods for using pseudo-viruses, including those derived from the herpes and papillomaviruses, to deliver drugs to keratinocytes and basal membrane cells for the treatment of skin genetic disorders including Pachyonychia Congenita and Xeroderma Pigmentosum. | 01-10-2013 |
| 20160046671 | STABILIZED SOS1 PEPTIDES - Provided herein are polypeptides containing stabilized therapeutic peptides related to KRAS guanidine exchange factor (SOS1). Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that includes administering to a subject one of the polypeptides. This disclosure relates to structurally stabilized therapeutic peptides related to KRAS guanidine exchange factor (SOS1), and methods of using such peptides in the treatment of cancer. | 02-18-2016 |
| 20100240594 | TARGETED DELIVERY OF CHEMOTHERAPEUTIC AGENTS - The disclosure provides compounds and compositions, and methods of using these compounds and compositions, for the targeted delivery of chemotherapeutic agents. | 09-23-2010 |
| 20130023481 | Adenovirus E1A Fragments for Use in Anti-Cancer Therapies - The present invention relates to an improved cancer therapy comprising co-administration with the E1A 1-80 transcription-repression domain activity. In addition, E1A 1-80 can act as a monotherapy against cancers that express elevated HER2/Neu or in combination with anti-HER2/Neu, chemo- or radiotherapeutic treatments. | 01-24-2013 |
| 20140088019 | Monovalent and Multivalent Multispecific Complexes and Uses Thereof - Monovalent and multivalent multispecific complexes including ELP-MRD fusion proteins containing one or more modular recognition domains (MRDs) that bind target antigens are described. The use of these monovalent and multivalent multispecific complexes (e.g., ELP-MRD fusion proteins) in diagnostic, prognostic, and therapeutic applications and methods of making these complexes are also described. | 03-27-2014 |
| 20150297590 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY - Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer. | 10-22-2015 |
| 20150051154 | ALKYLATING AGENTS - The present invention relates to a novel class of alkylating agents comprising a thieno-indole moiety linked to a DNA-binding moiety, which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical composition containing them. The invention also relates to the use of this novel class of alkylating agents in the preparation of conjugates. | 02-19-2015 |
| 20120021994 | NOVEL CANCER ANTIGEN EEF2 - The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject. | 01-26-2012 |
| 20120021996 | USING HEAT SHOCK PROTEINS TO IMPROVE THE THERAPEUTIC BENEFIT OF A NON-VACCINE TREATMENT MODALITY - The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or α2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality. | 01-26-2012 |
| 20120021995 | Polypeptides that Bind TRAIL-R1 and TRAIL-R2 - Agonists for TRAIL death receptors including polypeptides that bind to TRAIL death receptor TRAIL-R1 (DR4) and/or TRAIL-R2 (DR5) and optionally having a multimerizing, e.g. trimerizing domain. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes. | 01-26-2012 |
| 20130090293 | PROTEIN SCAFFOLDS FOR TARGETED DELIVERY OF TOXIC IRON TO CANCER CELLS - Described herein are modifications and adaptations of iron storage proteins for a novel photo-initiated approach to cancer therapy whereby cells are killed via production of iron-generated hydroxyl radicals. The iron is photo-released from a protein scaffold that includes tumor-targeting peptides and/or proteins fused to the exterior surface of the protein scaffold. One or more photosensitizers are coupled to the protein shell. The multiple tumor-targeting peptides and/or proteins will bind to specific hyperexpressed receptors on the cancer cells. After binding of the photosensitizer-iron-loaded protein to the cancer cells, photochemical excitation of the photosensitizers with tissue-penetrating near-infrared light triggers release of “free” ferrous iron, which in oxic or mildly hypoxic intracellular environments generates toxic hydroxyl radicals via Fenton chemistry. This light-triggered release of “free” iron overwhelms the cancer cells' defenses against free radicals. The combination of tumor-targeting peptides and photo-triggered release of iron ensures that non-cancerous cells are not bombarded with iron. | 04-11-2013 |
| 20140274909 | ANTI-CD22 CHIMERIC ANTIGEN RECEPTORS - The disclosure provides a chimeric antigen receptor (CAR) comprising a) an antigen binding domain of HA22, a transmembrane domain, and an intracellular T cell signaling domain; or b) an antigen binding domain of BL22, a transmembrane domain, and an intracellular T cell signaling domain comprising CD28 and/or CD137. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. | 09-18-2014 |
| 20140274908 | EPIGENETIC BIOMARKER ADAMTS9 FOR DIAGNOSIS AND PROGNOSIS OF GASTRIC CANCER - The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the ADAMTS9 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing ADAMTS9 gene expression or activity. | 09-18-2014 |
| 20130059792 | Traceability of Cellular Cycle Ano - The present invention relates to the field of medicine and biology. It concerns a novel test for screening and for therapeutic follow-up in oncology. More particularly, it relates to diagnostic and/or therapeutic tests in oncology and on neurodegenerative diseases. It is a diagnostic test and a prognostic test for various cancers (breast cancer, bladder cancer, ovarian cancer, lung cancer, skin cancer, prostate cancer, colon cancer, liver cancer, glioblastoma, sarcoma, leukemia, etc.) and therapeutics solutions for specific neurodegenerative diseases. More particularly, the invention concerns the use of the LIV21 protein, LIV21 gene and of derivatives thereof as diagnostic and prognostic markers for cancers. The invention therefore concerns the detection of the LIV21 protein with a kit comprising LIV21-specific antibodies. | 03-07-2013 |
| 20120021997 | USING HEAT SHOCK PROTEINS TO IMPROVE THE THERAPEUTIC BENEFIT OF A NON-VACCINE TREATMENT MODALITY - The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or α2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality. | 01-26-2012 |
| 20140336129 | Targeting the EGFR-SGLT1 Interaction for Cancer Therapy - A compound can destabilize a binding interaction between an epidermal growth factor receptor (EGFR) and a sodium/glucose co-transporter 1 (SGLT 1). In one embodiment, the compound is a peptide derived from the interacting domain of EGFR. In another embodiment, the peptide is administered to a patient to treat cancer. | 11-13-2014 |
| 20120245100 | PLASMID FOR EXPRESSION OF TRANSGENES IN PLANTS - A plasmid for use in transferring a chicken anemia virus apoptin coding sequence into a plant includes a binary vector suitable for transferring DNA from | 09-27-2012 |
| 20120071417 | METHODS OF INHIBITING CANCER CELL GROWTH WITH HDAC INHIBITORS AND METHODS OF SCREENING FOR HDAC10 INHIBITORS - Methods of inhibiting cancer cell growth using HDAC10 inhibitors are provided. Methods of treating cancer in a subject using HDAC10 inhibitors are also provided. In certain embodiments, at least one second inhibitor selected from an autophagy inhibitor, an AMPK inhibitor, and methyl pyruvate is also used in the methods. Dose packs comprising HDAC10 inhibitors and at least one second inhibitor are provided. Methods of identifying HDAC10 inhibitors are also provided. | 03-22-2012 |
| 20130018002 | COMPOSITIONS AND METHODS FOR TREATING AIDS OR CANCER BY INHIBITING THE SECRETION OF MICROPARTICLES - Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides. | 01-17-2013 |
| 20140018303 | 3-Amino-2-Hydroxy-4-Phenylbutanoyl-Valyl-Isoleucine, Preparation and Use Thereof - The present invention relates to a novel compound, 3-amino-2-hydroxy-4-phenylbutanoyl-valyl-isoleucine with structure showed below. | 01-16-2014 |
| 20130196929 | SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE (SPARC) AS CHEMOTHERAPEUTIC SENSITIZERS - The present invention relates to compositions and methods of use thereof for cancer therapy sensitization. Such compositions comprise functional fragments of the nucleotide and/or polypeptide sequences of a Secreted Protein Acidic and Rich in Cysteine (SPARC). The compositions can be used in combination with existing chemotherapeutic agents for treatment of cancers. | 08-01-2013 |
| 20130116196 | MUSCLE FATIGUE SUBSTANCE CYTOKINES AND METHODS OF INHIBITING TUMOR GROWTH THEREWITH - Compositions and methods for inhibiting tumor growth and tumor cell proliferation are provided. In general, the cytokines useful with the present invention are selected from the group consisting of LIX (or CXCL | 05-09-2013 |
| 20150292032 | TREATMENT OF CANCER BY TARGETING QUIESCENT CANCER CELLS - A method for treating a subject suffering from a neoplasm, comprising determining the expression level of a DYRK1 selected from DYRK1A or DYRK1B within a cell population in a sample of neoplastic cells and determining the quiescent state of these cells, and if the DYRK1 is expressed in the sample then administering an effective amount of a modulator of DYRK1 activity, either alone or as a part of a combination therapy. | 10-15-2015 |
| 20120065146 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE - Found in various eukaryotic organisms, polo-like kinases (collectively, Plks) are a conserved subfamily of Ser/Thr protein kinases that play critical roles in cell proliferation. Provided herein are compounds that specifically inhibit the activity of Plks, specifically Plk1. Further provided herein are methods for use of the compounds for the treatment of hyperproliferative disorders, particularly cancer. Also provided are uses of the compounds for the preparation of a medicament. | 03-15-2012 |
| 20150018286 | ANTITUMOR PEPTIDE AND USE THEREOF - This invention provides an antitumor peptide and an antitumor composition that includes the peptide for suppressing proliferation of at least one species of tumor cells. The antitumor composition provided by this invention includes an antitumor peptide capable of inducing formation of multipolar spindles in at least one species of tumor cells, and at least one species of pharmaceutically acceptable carrier, wherein the antitumor peptide is a synthetic peptide having an amino acid sequence selected from SEQ ID NOs: 1 to 22 or an amino acid sequence formed by substituting, deleting and/or adding one, two or three amino acid residues in/from/to the selected amino acid sequence. | 01-15-2015 |
| 20130018001 | METHODS OF DIAGNOSING CANCER - Provided are methods of predicting or assessing the level of severity of cancer or cancer progression in a patient comprising measuring levels of SET expression in a biological sample from a patient and comparing levels of SET expression to a control sample or standard value. Methods for predicting or evaluating the efficacy of a SET therapeutic and kits comprising at least one reagent for measuring SET protein expression are also provided. | 01-17-2013 |
| 20150291658 | NOVEL CHONDRAMIDE DERIVATIVES - The present invention provides novel chondramide derivatives of formula (I) which can be used for the treatment of cancer. | 10-15-2015 |
| 20120040914 | ENHANCING EFFECTIVENESS OF GLIAL CANCER THERAPIES - A method of enhancing the effectiveness of a chemotherapeutic agent, such as Temozolomide (TMZ), or ionizing radiation against glioblastoma is described in the present invention. The method comprises targeting putative membrane androgen receptor (termed mAR) in glioma cells to enhance the cytotoxic effects of a chemotherapeutic agent or ionizing radiation while simultaneously affording protection to neighboring neurons. | 02-16-2012 |
| 20130157960 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF - The present application relates to novel derivatives of monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and also to the use of these derivatives for preparing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as, for example, cancerous disorders. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 06-20-2013 |
| 20130102542 | CANCER RELATED ISOFORMS OF COMPONENTS OF TRANSCRIPTION FACTOR COMPLEXES AS BIOMARKERS AND DRUG TARGETS - The invention is related to isoforms of components of transcription factor complexes that are specifically expressed in cancer cells. These isoforms can be used as biomarkers for detection, diagnosis, prognosis and monitoring of treatments of cancer, and as drug targets of pharmaceutical compositions for the treatment of various cancers expressing the targeted isoforms. Methods, molecules, materials and kits for these uses are disclosed. | 04-25-2013 |
| 20120004181 | TARGETED DELIVERY SYSTEM - The present invention relates a targeted delivery system for siRNA or antisense technology. In one embodiment, the invention provides for a method of treating cancer by administering a therapeutically effective dosage of HerPBK10 combined with siRNA, resulting in the inhibition of Her2 expression and cell death. In another embodiment, a plurality of HerPBK10 combined with siRNA form a nanoparticle. | 01-05-2012 |
| 20150361138 | KISS1R RECEPTOR AGONIST COMPOUNDS AND USE THEREOF FOR INDUCING OVULATION IN MAMMALS - A KISS1R agonist peptide compound capable of inducing ovulation in a female mammal is provided. The compound is a pseudopeptide having the C-terminal sequence: -XaaΨ[Tz]Xaa2-Xaa3-Xaa4-NH | 12-17-2015 |
| 20120046233 | MUTATIONS IN THE LNK GENE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND OTHER HEMATOLYMPHOID MALIGNANCIES - Aspects of the present invention include methods, compositions and kits for classifying a subject as having or being predisposed to a hematolymphoid neoplasm or malignancy if they harbor a mutation in the LNK gene. Aspects of the present invention also include screening for candidate agents for treating LNK mutation-based hematolymphoid neoplasms or malignancies in cell-based and cell free assays as well as therapeutic compositions for treating a LNK-mutant based hematolymphoid disorder. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. | 02-23-2012 |
| 20140088020 | Composition and Methods for Treatment of Cancer - The present invention contemplates therapeutic constructs comprising wild type SEG superantigen, its homologues and tumor targeting fusion proteins devoid of neutralizing antibodies in human sera for treatment of cancer | 03-27-2014 |
| 20120071419 | Target-Specific Non-Antibody Protein and Method for Preparing the Same - The present invention relates to a method for preparing a target-specific non-antibody protein, and more particularly, to a method for preparing a target-specific non-antibody protein comprising the steps of: selecting non-antibody proteins having a structural complementarity with the target site of a target protein in a non-antibody protein library; calculating a binding energy of the selected non-antibody protein and the target protein; selecting a non-antibody protein having a favorable binding energy among the selected non-antibody proteins; selecting amino acid residues having a high binding energy among the interfacial amino acid residues of the selected non-antibody protein and the target protein; and substituting the selected amino acid residues with the amino acid residues having a low binding energy. In addition, the present invention relates to a target-specific non-antibody specifically binding with EGFR (Epidermal Growth Factor Receptor) domain 2, which is prepared by the method, and a cancer therapeutic composition comprising the same. | 03-22-2012 |
| 20130303461 | METHODS FOR DETERMINING A NUCLEOTIDE SEQUENCE - The technology described herein is directed to methods of determining oligonucleotide sequences, e.g. by enriching target sequences prior to sequencing the sequences. | 11-14-2013 |
| 20150087599 | Peptide-Conjugated Oligonucleotide Therapeutic and Method of Making and Using Same - Conjugates for the efficient delivery of sequence-specific antisense to cells of a selected type for the inhibition of a target protein have the general formula: | 03-26-2015 |
| 20120108521 | IMMUNOSTIMULATORY COMPOSITIONS AND USES THEREOF - The present invention provides novel immune-stimulatory polypeptides, and methods for their use and identification. | 05-03-2012 |
| 20150025017 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present disclosure provides compositions and methods for treating cellular hyperproliferative disorders with a PHF5α inhibitor, such as siRNA, shRNA, antisense oligonucleotides, or pharmaceutical compounds. Exemplary cellular hyperproliferative disorders that can be treated with the PHF5α antagonists of the present disclosure include cancers, such as gliomas, adenocarcinomas, cervical cancer or prostate cancer. | 01-22-2015 |
| 20150025016 | PEPTIDES THAT INHIBIT THE INTERACTION BETWEEN ASF1 AND HISTONES, AND USE THEREOF - The present invention relates to peptides capable of inhibiting the formation of the complex between the Asf1 histone chaperone and histones H3-H4, and to the use thereof as a drug, particularly for treating cancer. | 01-22-2015 |
| 20130172266 | MITOCHONDRIAL PENETRATING PEPTIDES AS CARRIERS FOR ANTICANCER COMPOUNDS - There is described herein compounds comprising a mitochondrial penetrating peptide (MPP) conjugated to an anti-cancer compound, and their method of use. | 07-04-2013 |
| 20120010151 | USE OF WNT5-A PEPTIDE DERIVATES FOR THE TREATMENT OF MELANOMA AND GASTRIC CANCER - The present invention relates to a novel unbranched carbamate derivative, in particular N-butyloxycarbonyl derivative of certain Wnt5-α peptides and to their use in the treatment of melanoma or gastric cancer, as well as a method for treating melanoma as well as a pharmaceutical composition comprising the same derivative. | 01-12-2012 |
| 20140213529 | PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES - The invention provides a | 07-31-2014 |
| 20150361147 | NOVEL CANCER ANTIGEN EEF2 - The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject. | 12-17-2015 |
| 20130157959 | USE OF HADES AS TUMOR SUPPRESSOR TARGET - The present invention relates to a new use of Hades as a tumor suppressor target, more particularly to a composition for suppressing tumor comprising an expression or action inhibitor of Hades protein having an amino acid sequence of SEQ ID NO: 2 as an effective ingredient. The present inventors have found that the overexpressed Hades protein interacts with p53 to inhibit the exonuclear mechanism of p53 and the knowdown of Hades induces increase in the expression of p53, demonstrating that Hades is a negative regulator to p53. Therefore, it would be understood that the inhibition of Hades overexpressed in tumor cells contributes to tumor-supressive effects of p53. The drug candidates capable of modulating the expression of the Hades protein, inhibiting the actions of the Hades protein or inhibiting interecation between Hades and p53 are considered a promising anticancer drug. | 06-20-2013 |
| 20140024602 | POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT AND PREVENTION OF DISORDERS ASSOCIATED WITH PROGENITOR CELL MOBILIZATION - Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided. | 01-23-2014 |
| 20150359843 | P53 ACTIVATING PEPTIDES - The present invention is directed to p53 activating peptides. The present further describes methods for generating these peptides and the use of these peptides. | 12-17-2015 |
| 20150359837 | pH-Sensitive Polymer-Drug Conjugates for Targeted Delivery of Therapeutics - Polymeric delivery systems for boronic acid-containing therapeutics, related compounds and methods of use, for a pH-sensitive chemoselective approach to delivery of such a therapeutic. | 12-17-2015 |
| 20150087598 | TREATING MUC1-EXPRESSING CANCERS WITH HELICASE INHIBITORS - The invention provides method of treating cancers that express MUC1 by the administration of eIF4A helicase inhibitors. These inhibitors may advantageously be combined with peptides that inhibit MUC1 oligomerization, or with other standard anticancer therapies such as chemo-, radio- and surgical therapies. | 03-26-2015 |
| 20130190249 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE - Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here. | 07-25-2013 |
| 20140213530 | METHODS FOR TREATMENT OF CANCER BY TARGETING SIRT5 - This disclosure demonstrates that inhibition of Sirt5 can suppress malignant transformation of cells. Therefore, methods of treating cancer based on inhibition of Sirt5 are disclosed. | 07-31-2014 |
| 20120065145 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER - This application provides compositions and methods useful in the treatment of certain cancers. In part, this application is based on the recognition that certain molecules that target abasic lesions or AP sites in DNA improve, augment, or potentiate the chemotherapeutic efficacy of certain anticancer agents. | 03-15-2012 |
| 20140094416 | SPARC ANGIOGENIC DOMAIN AND METHODS OF USE - The invention provides compositions and methods which exploit the discovery of the SPARC carboxy angiogenic domain. | 04-03-2014 |
| 20130210742 | SUSTAINED-RELEASE FORMULATION - The present invention relates to a sustained-release formulation comprising a metastin derivative and a lactic polymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof. The sustained-release formulation of the present invention slowly and stably releases compound (I) or a salt thereof over a long period of time and exerts medicinal effects of compound (I) or a salt thereof over a long period of time. Furthermore, the sustained-release formulation of the present invention, which improves patient's convenience by reducing frequency of administration, is an excellent formulation as a clinical medicine. | 08-15-2013 |
| 20130217636 | COMPOSITIONS AND METHODS FOR TREATMENT OF GYNECOLOGIC CANCERS - Molecules and compositions that can be used in the treatment of gynecologic cancers are described. ApoA-1, in particular, is demonstrated to inhibit the proliferation of cancer cells reduce tumor size in a mouse model of ovarian cancer. | 08-22-2013 |
| 20120071420 | MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS - The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4 | 03-22-2012 |
| 20120165269 | Tumor Cell-Killing Peptides - The present invention provides a tumor cell-killing peptide and a pharmaceutical composition for treating a cancer. The tumor cell-killing peptide of the present invention selectively homes into tumor cells so that it can induce the death of tumor cells effectively while minimizing the harming of normal cell. | 06-28-2012 |
| 20120165268 | P53 FUSION PROTEINS AND METHODS OF MAKING AND USING THEREOF - Biologically active tetrameric p53 proteins and p53 fusion proteins are provided. These proteins may be generated and refolded into tetrameric form using denatured proteins produced from | 06-28-2012 |
| 20140235551 | INHIBITORS OF IAP - Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: | 08-21-2014 |
| 20140235550 | Antineoplastic Hydrogels, and Enzyme-Instructed Preparations Thereof - Disclosed is a general methodology to create nanofibers of therapeutic molecules that have a dual role, as both the delivery vehicle and the drug itself. It is shown that with proper molecular design, the integration of enzymatic reaction and self-assembly provides a powerful method to create molecular hydrogels of clinically-used therapeutics without compromising their bioactivities. In addition, the results disclosed herein demonstrate enzyme-instructed self-assembly as a facile strategy for generating the supramolecular hydrogels of molecules that inherently have poor solubility in water. For example, by covalently connecting paclitaxel with a motif that is prone to self-assemble, a hydrogel of paclitaxel can be formed without compromising the activity of the paclitaxel. | 08-21-2014 |
| 20140235548 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION - Compounds, pharmaceutical compositions, and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by JAMM proteins are disclosed. The compounds and compositions inhibit the enzymatic activity of a JAMM domain, including the JAMM domain of the CSN5 subunit of the COP9-signalsome (CSN), the JAMM domain of the Rpn11/Poh1/Psmd14 subunit of the 26S proteasome, the JAMM domain of AMSH, the JAMM domain of AMSH-LP, the JAMM domain of BRCC36, among other JAMM domains. | 08-21-2014 |
| 20150031625 | TARGETED VECTORS FOR CANCER IMMUNOTHERAPY - This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject. Also provided are a kit or drug delivery system comprising the compositions for use in the methods described. | 01-29-2015 |
| 20150031624 | ANTI-MESOTHELIN CHIMERIC ANTIGEN RECEPTORS - The invention provides a chimeric antigen receptor (CAR) (a) an antigen binding domain of HN1 or SS, a transmembrane domain, and an intracellular T cell signaling domain, or (b) an antigen binding domain of SS1, a transmembrane domain, an intracellular T cell signaling domain, and a granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor 2 leader. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. | 01-29-2015 |
| 20120077755 | Compounds For, and Methods of, Treating Cancer and Inhibiting Invasion and Metastases - Invasion-inhibiting peptides comprising either a modified cysteine (where the sulfur atom is modified with a alkyl group or other suitable group), and/or b) D-amino acids, for the treatment “cancer” in humans and animals. Such peptides can be used together with other therapies (e.g. radiation) to enhance the therapeutic benefit and reduce invasiveness. | 03-29-2012 |
| 20120302509 | COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS - The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from | 11-29-2012 |
| 20120122797 | PEPTIDIC COMPOUND AND USE OF SAME - An object of the present invention is to provide a novel compound having an antitumor/anticancer effect. Specifically, the present invention provides a compound represented by Formula (I), a derivative thereof or a salt of the same. In Formula (I), R | 05-17-2012 |
| 20120122796 | CELL PERMEABLE P53 RECOMBINANT PROTEIN, POLYNUCLEOTIDE ENCODING THE SAME, AND ANTI-CANCER COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT - Disclosed are a cell-permeable p53 recombinant protein in which a macromolecule transduction domain (MTD) is fused to the tumor suppressor p53, a polynucleotide encoding the same, a recombinant expression vector for producing the same, and a pharmaceutical composition of the treatment of cancer, comprising the same. Having high cell permeability, the p53 recombinant protein is effectively transduced into cells so that the tumor suppressor p53 can be translocated into cell nuclei. Within nuclei, p53 inhibits the formation of cyclin-CDK complexes to halt the cell cycle, thus suppressing excessive cell proliferation and inducing apoptosis of tumor cells. Therefore, the p53 recombinant protein can be useful as an anticancer agent in the treatment of various cancers. | 05-17-2012 |
| 20120083455 | HYMAN SERUM ALBUMIN-siRNA NANO-SIZED CARRIER SYSTEM - Disclosed are a human serum albumin-siRNA carrier system having siRNA bound to human serum albumin and a user thereof, and especially, human serum albumin-siRNA carrier system, which has a biodegradable covalent bond between human serum albumin polymer and siRNA and is stable in a living body, and a user thereof. | 04-05-2012 |
| 20120083454 | EPH RECEPTOR EXPRESSION IN TUMOR STEM CELLS - The present disclosure concerns the field of malignant tumors of the central nervous system and provides pharmaceutical compositions suitable for the therapeutic and for the prophylactic treatment of brain tumors and for inhibiting the growth of the tumor mass. | 04-05-2012 |
| 20110294743 | METASTASIS-SPECIFIC PEPTIDES AND THEIR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention concerns peptide sequences that specifically recognize cells of human hepatic metastases. The invention comprises also the use of nucleic acids coding for such peptides, as well as conjugates and formulations of such peptides for diagnostic and therapeutic purposes. | 12-01-2011 |
| 20160008378 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS BY STIMULATING ER STRESS | 01-14-2016 |
| 20110312898 | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER - A prophylactic/therapeutic agent for androgen-independent cancer is provided. A prophylactic/therapeutic agent for androgen-independent cancer includes a metastin derivative, and is particularly useful as a prophylactic/therapeutic agent for androgen-independent cancer, in particular, androgen-independent prostate cancer. | 12-22-2011 |
| 20130274202 | Peptides for Treating Cancer - The present invention relates to peptide from 4 to 50 amino acids comprising a phosphorylated pYX | 10-17-2013 |
| 20130274201 | SELECTIVE ANTICANCER CHIMERIC PEPTIDE - It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved. | 10-17-2013 |
| 20130274200 | SELECTIVE ANTICANCER CHIMERIC PEPTIDE - It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved. | 10-17-2013 |
| 20120094924 | NUCLEIC ACID DELIVERY COMPOUNDS - Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell. | 04-19-2012 |
| 20120094923 | METHODS AND MATERIALS FOR ASSESSING PROSTATE CANCER RECURRENCE AND REDUCING MESOTRYPSIN ACTIVITY - This document provides methods and materials involved in assessing prostate cancer recurrence and reducing mesotrypsin activity. For example, methods and materials for using expression levels of PRSS3 nucleic acid to determine whether a prostate cancer patient having undergone prostatectomy is likely to experience prostate cancer recurrence are provided. In addition, methods and materials for reducing mesotrypsin activity are provided. | 04-19-2012 |
| 20140349944 | CHAPERONE-BASED INTEGRIN INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES - The present disclosure provides isolated integrin αL polypeptides, such as α7 helix polypeptides from the alpha I domain of integrin. Such polypeptides inhibit the interaction between integrin and gp96, thereby inhibiting gp96 activity. Such inhibition can be used to prevent cancer cell growth, cancer metastasis and/or inflammation. | 11-27-2014 |
| 20110301092 | THE USE OF A NON-GLYCANATED POLYPEPTIDE FOR TREATING A CANCER - The use of a non-glycanated form of a polypeptide including an amino acid sequence having at least 90% amino acid identity with an amino acid sequence selected from the group consisting of SEQ ID No 1 and SEQ ID No 2 for manufacturing a medicament for preventing or treating a cancer. | 12-08-2011 |
| 20110306562 | Antisense EGFRAS Guanidinium Peptide Nucleic Acid (GPNA) Oligonucleotides as Antitumor Agents - A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In one embodiment, either systemic or intratumoral administration of antisense Epidermal Growth Factor Receptor (“EGFR”) GPNA oligonucleotides is believed to downmodulate EGFR levels, thus in turn to reduce head and neck squamous cell carcinoma tumor growth, which has been confirmed to date both in vitro and in vivo. | 12-15-2011 |
| 20110319336 | SELECTIVE ANTICANCER CHIMERIC PEPTIDE - It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved. | 12-29-2011 |
| 20110319337 | Dominant Negative WNT2 Compositions and Methods of Use - The present disclosure provides compositions, pharmaceutical preparations, kits and methods for inhibiting cell proliferation by contacting a cell expressing Fzd8 with a truncated Wnt2 polypeptide which acts as a dominant negative inhibitor of Fzd8 signaling. The present disclosure provides compositions, kits and methods for the detection of cancer by determining the level of Fzd8 and/or Wnt2 expression in a cell. | 12-29-2011 |
| 20110319335 | COMBINED ADMINISTRATION OF INTEGRIN RECEPTOR ANTAGONISTS FOR ANTI-ANGIOGENIC THERAPY - The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an αvβ3 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12). | 12-29-2011 |
| 20150099707 | MODIFIED PSEUDOMONAS EXOTOXIN A - The invention provides a | 04-09-2015 |
| 20130130991 | USE OF A PEPTIDE ENHANCING THE ABILITY OF RADIATION THERAPY TO KILL CANCER CELLS - The present invention relates to a peptide consisting essentially of the N2 sequence of the RasGAP protein, a bio logically active fragment thereof, or a variant thereof, which is useful for the preparation of a medicament for the treatment of cancer. Furthermore, it relates to a method of treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of the peptide of the invention. | 05-23-2013 |
| 20120220537 | 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES - N-substituted 9-aminoacridine and bis-acridino derivatives containing electron-withdrawing groups (EWG) or electron-donating groups (EDG), including amino acid residues, and one-pot methods for their synthesis are disclosed. The derivatives are potential candidates for cancer treatment. | 08-30-2012 |
| 20150366984 | SOLUBLE COMPLEXES OF DRUG ANALOGS AND ALBUMIN - The present invention provides novel, non-covalently bound complexes of serum albumin and analogs of poorly soluble drugs, such as camptothecin. The novel complexes are significantly more water-soluble than the camptothecin analogs and are useful as prodrug forms of the camptothecin analogs for the treatment of mammalian cell proliferative diseases, such as cancer. | 12-24-2015 |
| 20150366936 | INHIBITION OF DRUG RESISTANT CANCER CELLS - Provided herein are methods of treating cancer in a cancer patient by overcoming resistance of a cancer cell to a drug, or methods of overcoming resistance of a cancer cell to a drug, comprising administering to the patient an effective amount of (i) an EGFR tyrosine kinase inhibitor or a B-Raf kinase inhibitor, and (ii) an HDAC inhibitor. Also provided are methods for inhibiting or preventing proliferation of drug tolerant persister (DTP) cells comprising contacting these cells with an EGFR tyrosine kinase inhibitor or B-Raf kinase inhibitor in combination with an HDAC inhibitor. Yet also provided are methods for inhibiting or preventing formation of colonies of drug tolerant expanded persister (DTEP) cells comprising contacting these cells with an EGFR tyrosine kinase inhibitor or B-Raf kinase inhibitor in combination with an HDAC inhibitor. | 12-24-2015 |
| 20110230420 | RELEASABLE CONJUGATES FOR NUCLEIC ACIDS DELIVERY SYSTEMS - The present invention is directed to nucleic acids delivery systems and methods of modulating an expression of a target gene using the same. In particular, the invention relates to nucleic acids conjugates containing an endosomal release-promoting moiety. The nucleic acids conjugates further contain a nuclear localization signal moiety, and/or a cell targeting moiety. | 09-22-2011 |
| 20110230419 | IAP BINDING COMPOUNDS - The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, that bind to Inhibitor of Apoptosis Proteins (IAPs). The compounds of the invention may be used as diagnostic and therapeutic agents in the treatment of proliferative diseases, such as cancer, for promoting apoptosis in proliferating cells, and for sensitizing cells to inducers of apoptosis. The present invention furthermore provides a polymeric compound of formulas (VI) or (VII), comprising either at least two monomeric units of compounds of formula (I), or at least one monomeric unit of a compound of formula (I) and an entity E. The present invention further relates to pharmaceutical compositions comprising said compounds of formulas (I), (VI), and (VII) and the use of said compounds in medicine. | 09-22-2011 |
| 20110230418 | Anticancer Agent - The present invention is an antineoplastic agent characterized by including at least one of taxol and taxol derivatives and a protein which is a mutant of diphtheria toxin, having an activity to inhibit a binding between HB-EGF and EGFR and substantially not having a toxicity of diphtheria toxin as active ingredients. | 09-22-2011 |
| 20140378390 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 12-25-2014 |
| 20140045769 | HYDROGEN BOND SURROGATE MACROCYCLES AS MODULATORS OF RAS - The present invention relates to peptides having one or more stable, internally-constrained HBS α-helices, where the peptide is capable of interacting with Ras and related proteins. | 02-13-2014 |
| 20100286060 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOEITIN-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 11-11-2010 |
| 20100292165 | Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation - The invention relates to the field of biochemistry and medicine. More specifically, the invention relates to methods and pharmaceuticals for the treatment of intestinal neoplasia. The invention discloses the surprising finding that inhibitors of Notch pathway activation (for example, γ-secretase inhibitors) are extremely useful in the treatment of intestinal adenoma and/or adenocarcinoma. | 11-18-2010 |
| 20100292163 | Antitumoral Compounds - Antitumoral compounds of Formula I, and pharmaceutically acceptable salts, derivatives, tautomers, prodrugs or stereoisomers thereof | 11-18-2010 |
| 20120270798 | Compositions and Methods for Preventing or Treating Cancer - The present invention relates to a MUC1 cytoplasmic tail peptide or portion thereof. These peptides are useful for inducing an immune response to MUC1-expressing tumor cells and thus for preventing or treating cancer. | 10-25-2012 |
| 20120270797 | ENGINEERED PROTEINS INCLUDING MUTANT FIBRONECTIN DOMAINS - The present invention features engineered proteins that can include a genetically modified Fn domain; two or more such domains joined to one another; or at least one genetically modified Fn domain joined to a target-specific protein scaffold. One or more accessory sequences can be included in or added to any of these configurations. Methods of use, including methods of treating cancer, with the engineered proteins are also disclosed. | 10-25-2012 |
| 20120245101 | SYNTHETIC APOLIPOPROTEIN E MIMICKING POLYPEPTIDES AND METHODS OF USE - The present invention provides novel synthetic apolipoprotein E (ApoE)-mimicking peptides wherein the receptor binding domain of apolipoprotein E is covalently linked to 18A, the well characterized lipid-associating model class A amphipathic helical peptide, or a modified version thereof. Such peptides enhance low density lipoprotein (LDL) and very low density lipoprotein (VLDL) binding to and degradation by fibroblast or HepG2 cells. Also provided are possible applications of the synthetic peptides in lowering human plasma LDL/VLDL cholesterol levels, thus inhibiting atherosclerosis. The present invention also relates to synthetic peptides that can improve HDL function and/or exert anti-inflammatory properties. | 09-27-2012 |
| 20120245099 | APOPTOSIS INDUCER - The present invention provides an apoptosis-inducing agent capable of inducing apoptosis in various cells including tumor cells and other cells in a simple manner, etc. The apoptosis-inducing agent of the present invention comprises a peptide shown in (a) or (b) below, a derivative thereof, or a salt of the peptide or the derivative: (a) a peptide which comprises an amino acid sequence represented by the formula: C—X-D-X—X—X—X—Y—X—C—X—C (SEQ ID NO: 1)(I); or (b) a peptide which comprises an amino acid sequence with deletion, substitution or addition of one or several amino acids in the amino acid sequence represented by formula (I) and which has apoptosis-inducing activity. | 09-27-2012 |
| 20120252736 | METHODS INVOLVING PDGFRBETA INHIBITORS - The invention refers to PDGFRbeta inhibitor for use in the antiproliferative treatment of T-cell lymphoma, in particular NHL, ALCL and PTCL. | 10-04-2012 |
| 20130288983 | VARIANT ACTIVIN RECEPTOR POLYPEPTIDES AND USES THEREOF - The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided. | 10-31-2013 |
| 20130288982 | THERAPEUTIC AGENT FOR PULMONARY SMALL CELL CARCINOMA - The invention aims to clarify further functions of a T-cell leukemia translocation-associated gene (TCTA) protein-derived peptide and provide a novel application of the peptide. The invention provides a therapeutic agent for pulmonary small cell carcinoma or a cell growth inhibitor of pulmonary small cell carcinoma, comprising any peptide described in SEQ ID NOs 1 to 5. | 10-31-2013 |
| 20130288981 | TARGETING SENESCENT CELLS AND CANCER CELLS BY INTERFERENCE WITH JNK AND/OR FOXO4 - The present invention relates to uses of agents that inhibit Jun kinases and/or FOXO4 in treating cancer and/or removing senescent cells in an individual. | 10-31-2013 |
| 20130288980 | TARGETING SENESCENT AND CANCER CELLS FOR SELECTIVE KILLING BY INTERFERENCE WITH FOXO4 - The present invention relates to agents that inhibit FOXO4 function and uses thereof in treating cancer and/or removing senescent cells in an individual. | 10-31-2013 |
| 20150306241 | COPOLYMERS FOR THE DELIVERY OF DRUGS INTO CELLS - Provided is a co-polymer of formula A-B-C or a pharmaceutically acceptable salt thereof, where A comprises a water soluble polymer; B comprises a matrix metalloprotease (MMP)-cleavable polypeptide; C is a chemotherapeutic drug or a derivative thereof; and A is connected to B at a first end through a first covalent bond or a first linking moiety and B is connected to C at a second end through a second covalent bond or a second linking moiety, where the co-polymer is not cross-linked. | 10-29-2015 |
| 20120178698 | Agents and Uses Thereof - The present invention provides agents capable of activating Sox11 for use in medicine. In particular, the agents of the invention are useful in the treatment of cancers, such as lymphomas (e.g. mantel cell lymphoma). The invention further provides pharmaceutical compositions of the agents of the invention, as well as methods and uses of the same. | 07-12-2012 |
| 20120277163 | MicroRNA-10 Antagonists and MicroRNA-10 Targets for Use in the Treatment of a Glioma - The present invention embraces microRNA-antagonists and activators of homeobox D10 protein; Zinc finger, MYND domain containing 11 protein; or RB1-inducible coiled-coil 1 protein for use in decreasing glial tumor cell proliferation and treating glioma. | 11-01-2012 |
| 20160061841 | NRF2-BASED CANCER TREATMENT AND DETECTION METHODS AND USES - Disclosed herein, inter alia, are methods and uses for treating a cancer in a subject. In various embodiments, a method or use includes measuring expression of nuclear factor erythroid-2 related factor 2 (NRF2), or an NRF2 target gene, in a candidate subject having cancer, or a cancer sample from the candidate subject, and determining the amount of NRF2 in the sample or in the subject having cancer, then comparing the amount of NRF2 determined, or NRF2 target gene determined, to a baseline or reference amount of NRF2 or NRF2 target gene. If the amount of NRF2 or NRF2 target gene in the sample or in the subject having cancer is less than the baseline or reference amount of NRF2 or NRF2 target gene, the subject having the cancer may be or is treated with a peptide or peptidomimetic sequence set forth herein, such as P1, P2, P3, P4, P5, P6 (SEQ ID NO:1) or P6, P5, P4, P3, P2, P1 (SEQ ID NO:2), e.g., CBP501. | 03-03-2016 |
| 20140171375 | MACROMOLECULES - The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least two different terminal groups are attached including a pharmaceutically active agent and a pharmacokinetic modifying agent, the pharmaceutically active agent comprising a hydroxyl group and being attached to the surface amino group of the dendrimer through a diacid linker. Pharmaceutical compositions comprising the macromolecules and methods of treatment using the macromolecules are also described. | 06-19-2014 |
| 20140066384 | NOVEL GENES AND PROTEINS THAT HOME TO DEVELOPING MICROVESSELS - Described herein are polypeptides that home to developing microvasculature, (also referred to as developing microvessels), such as newly developing microvasculature in mammals, particularly in humans, and to DNA that encodes such polypeptides. These polypeptides are referred to herein as developing microvasculature homing polypeptides. In a specific embodiment, the homing peptides are collateral vessel endothelia (CVE) homing polypeptides, which have been shown to home to collateral vessel endothelia after ischemia. | 03-06-2014 |
| 20110201560 | PEPTIDES FOR INHIBITING THE HPV-E6 ONCOPROTEIN - The present invention is concerned with means and methods for diagnosing or treating HPV associated neoplasia or tumors. Specifically, it relates to a peptide comprising an amino acid sequence motif as shown in SEQ ID No: 1. Moreover, contemplated by the present invention are fusion polypeptides, polynucleotides, vectors and host cells based on said peptide. Furthermore, the peptides, fusion polypeptides, polynucleotides, and vectors are suitable as pharmaceutical compositions for treating HPV associated neoplasia or tumors. The peptides and fusion polypeptides are also suitable as diagnostic compositions for diagnosing HPV associated neoplasia or tumors. The present invention also refers to a method of identifying a compound capable of binding to the HPV E6 protein. Finally, a kit is provided for carrying out the aforementioned diagnosis or compound identification. | 08-18-2011 |
| 20110201561 | TREATMENT OF METASTATIC COLON CANCER WITH B-SUBUNIT OF SHIGA TOXIN - The present invention relates to compositions and methods for treating invasive or metastatic cancer, particularly metastatic colon cancer using the B-submit of shiga toxin. The invention further provides methods of identifying compounds usefully for the treatment of invasive or metastatic cancer, particularly metastatic colon cancer. | 08-18-2011 |
| 20140073583 | STABLE COMPOSITIONS OF PEPTIDE EPOXY KETONES - The invention relates to pharmaceutical compositions that provide improved solubility and stability for peptide epoxy ketones. More specifically, the invention relates to pharmaceutical compositions comprising the peptide epoxy ketone proteasome inhibitor carfilzomib. | 03-13-2014 |
| 20140073582 | INSECTICIDE CRY PROTEINS OF BACILLUS THURINGIENSIS WITH ANTI-CANCER ACTIVITY - The invention relates to nucleic acid molecules encoding insecticidal proteins of the Cry family, derived from | 03-13-2014 |
| 20140073581 | Hybrid Cyclic Libraries and Screens Thereof - Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits. | 03-13-2014 |
| 20160008382 | METHODS OF TREATMENT OF CANCER | 01-14-2016 |
| 20120252738 | Tubulin Inhibitors - The present invention relates to novel tubulin binding molecules of formula (I) and their use for the treatment of cancer and other diseases. | 10-04-2012 |
| 20140142043 | INHIBITION OF DRUG RESISTANT CANCER CELLS - Provided herein are methods of treating cancer in a cancer patient by overcoming resistance of a cancer cell to a drug, or methods of overcoming resistance of a cancer cell to a drug, comprising administering to the patient an effective amount of (i) an EGFR tyrosine kinase inhibitor or a B-Raf kinase inhibitor, and (ii) an HDAC inhibitor. Also provided are methods for inhibiting or preventing proliferation of drug tolerant persister (DTP) cells comprising contacting these cells with an EGFR tyrosine kinase inhibitor or B-Raf kinase inhibitor in combination with an HDAC inhibitor. Yet also provided are methods for inhibiting or preventing formation of colonies of drug tolerant expanded persister (DTEP) cells comprising contacting these cells with an EGFR tyrosine kinase inhibitor or B-Raf kinase inhibitor in combination with an HDAC inhibitor. | 05-22-2014 |
| 20140094417 | PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC T CELL AND/OR B CELL EPITOPES - The invention provides a | 04-03-2014 |
| 20110172162 | Chemotherapy involving antisense oligonucleotides for preventing and/or treating pulmonary fibrosis - The invention provides, in the treatment of malignant tumors, antisense DNA oligonucleotides which are effective in inhibiting the expression of a wild type COL1A1 gene, in combination with a chemotherapy drug, typically bleomycin, cyclophosphamide, or methotrexate, which otherwise is known to cause lung disease such as pulmonary fibrosis. | 07-14-2011 |
| 20140155333 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT USING TARGETED CARBON NANOTUBES - Compositions for detecting and/or destroying cancer tumors and/or cancer cells via photodynamic therapy are disclosed, as well as methods of use thereof. The compositions comprise a linking protein or peptide attached to or otherwise physically associated with a carbon nanotube to form a targeted protein-carbon nanotube complex. | 06-05-2014 |
| 20140155331 | NOVEL HIGH AFFINITY BIVALENT HELICALLY CONSTRAINED PEPTIDE AGAINST CANCER - The present invention describes a novel bivalent helically constrained peptide targeted against S100B that is an effective anti-cancer drug against cancers that over-express S100B. This helix mimetic targeted against S100B induces rapid apoptosis in cancer cells that over-express a calcium binding protein S100B through simultaneous inhibition of key growth pathways including activation of p53. | 06-05-2014 |
| 20140155332 | SELECTIVE INHIBITORS OF TUMOR-INITIATING CELLS - Described herein are novel malignancy associated gene signature biomarkers, and assays and methods thereof, to classify prognosis or malignant potential of a cancer and identify cancer-initiating cells. The malignancy associated gene signature biomarkers, assays and methods described herein provide, in part, new methodologies to screen for novel drugs for treating cancers and tumors, such as, for example, triple-negative breast tumors. Using the assays and methods described herein proteasome inhibitors, histone deacetylase inhibitors, and glycolysis inhibitors, were identified as being highly effective in altering gene expression signatures specifically in malignant or cancer-initiating cells. | 06-05-2014 |
| 20140107039 | POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) INHIBITORS AND USES THEREOF - The present invention relates to Polycomb Repressive Complex 2 (PRC2) peptide inhibitors and their use for the treatment of cancer and other conditions associated with aberrant PRC2 methyltransferase activity. | 04-17-2014 |
| 20160068569 | STRUCTURE-BASED PEPTIDE INHIBITORS OF P53 AGGREGATION AS A NEW APPROACH TO CANCER THERAPEUTICS - This invention relates, e.g., to an inhibitory peptide or CPP inhibitor which specifically binds to p53 having an aberrant conformation (e.g., is aggregated or misfolded) and inhibits p53 amyloidogenic aggregation or restores proper folding of the misfolded protein. Methods of using the inhibitory peptide or CPP inhibitor (e.g. to treat subjects having tumors that comprise aggregated p53) are described. | 03-10-2016 |
| 20160017292 | SELECTIVE TARGETING OF CANCER STEM CELLS - Aspects of the invention relate to methods and related compositions for preferentially targeting cancer stem cells. In some embodiments, the methods utilize PKC-α/FRA1 pathway inhibitors to target carcinoma cells. Also provided are methods for identifying a candidate compound for selectively inhibiting growth of cancer stem cell, and methods for obtaining cells that have undergone an epithelial to mesenchymal transition. | 01-21-2016 |
| 20140179618 | NOVEL CANCER THERAPIES AND METHODS - The present invention provides an inhibitor of the ubiquitin-proteasome system for use in treating cancer in a patient, wherein the patient is assessed to establish that the cancer is associated with cells in which the functional activity of SMARCB1 is low or absent. In one embodiment, the patient has, or is suspected of having, breast cancer, an atypical teratoid rhabdoid tumour (AT/RT) and/or a malignant rhabdoid tumour (MRT). In one embodiment, the proteasome inhibitor is Bortezomib. Further aspects of the invention provide related uses and methods. | 06-26-2014 |
| 20140005121 | OLIGOPEPTIDES AND PROCESS FOR PREPARATION THEREOF | 01-02-2014 |
| 20140005118 | BETA-CATENIN TARGETING PEPTIDES AND USES THEREOF | 01-02-2014 |
| 20140018302 | Cancer Therapies and Diagnostics - Compositions and methods for increasing p53-dependent transcriptional activity in a cell. | 01-16-2014 |
| 20140018304 | METHOD FOR SCREENING FOR A CANCER TREATMENT AGENT USING THE INTERACTION BETWEEN PAUF AND A BINDING PARTNER THEREOF - The present invention relates to a method for screening for a cancer treatment agent by contacting a test material with pancreatic adenocarcinoma upregulated factor (PAUF) and GLRX3, SNAPIN, or UBL4A, as a binding partner for PAUF, and then analyzing whether or not the test material inhibits the binding of the PAUF and GLRX3, SNAPIN, or UBL4A serving as a binding partner therefor, thereby determining that the test material is a cancer treatment agent if the binding is inhibited. The invention also relates to a pharmaceutical composition containing the test material as an active ingredient for inhibiting and treating cancer. The pharmaceutical composition of the present invention, which contains, as an active ingredient, an inhibitor for inhibiting PAUF from binding with a binding partner, effectively inhibits PAUF signaling related to the onset of cancer, thus enabling various kinds of cancer (especially pancreatic cancer) to be treated. | 01-16-2014 |
| 20140024600 | METHODS AND COMPOSITIONS FOR MODULATING DRUG-POLYMER ARCHITECTURE, PHARMACOKINETICS AND BIODISTRIBUTION - Drug-polymer chemotherapeutics are provided having improved therapeutic efficacy and reduced dose-limiting toxicity. Methods are also provided for modulating the architecture, pharmacokinetics and biodistribution of drug-polymers and for reducing the dependence of transition temperature on concentration for drug-polymers. | 01-23-2014 |
| 20140051642 | COMPOSITION COMPRISING AFLIBERCEPT, FOLINIC ACID, 5-FLUOROURACIL (5-FU) AND IRINOCETAN (FOLFIRI) - Pharmaceutical composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI) useful in the treatment of Colorectal cancer (CRC). | 02-20-2014 |
| 20140051641 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 02-20-2014 |
| 20140057852 | Treatment of Cancers with A-8R Peptide - The present invention provides materials and methods useful to treat various sGCα1-expressing cancers. Materials include peptides which interfere with sGCα1's pro-survival functions, thereby resulting in apoptosis of sGCα1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits. | 02-27-2014 |
| 20140057851 | Anti-Angiogenic Gene Therapy With Soluble VEGF Receptors -1, -2 and -3 Together With Paclitaxel Prolongs Survival Of Mice With Human Ovarian Carcinoma - Anti-angiogenic gene therapy with a combination of soluble Vascular Endothelial Growth Factors (sVEGFR) improves the efficacy of chemotherapy with paclitaxel for reducing ovarian cancer mean tumor volume (in cubic millimetres) as measured using magnetic resonance imaging. The study groups were: AdLacZ control, combination of AdsVEGFR-1, -2 and -3, combination of AdsVEGFR-1, -2, -3 and paclitaxel, bevacizumab monotherapy, paclitaxel monotherapy and carboplatin monotherapy. Effectiveness was assessed by survival time and surrogate measures such as sequential MRI, immunohistochemistry, microvessel density and tumor growth. Antiangiogenic gene therapy combined with paclitaxel significantly prolonged the mean survival compared to the controls and all other treatment groups (p=0.001). Tumors of the mice treated by gene therapy were significantly smaller than in the control group (p=0.021). The mean vascular density and total vascular area were also significantly smaller in the tumors of the gene therapy group (p=0.01). | 02-27-2014 |
| 20120277162 | POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH - In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases. | 11-01-2012 |
| 20120277161 | INHIBITION OF MULTIPLE CELL ACTIVATION PATHWAYS - There is provided a method for inhibiting growth and/or proliferation of a cancer cell. The method comprises treating a cancer cell with an effective amount of a polypeptide providing a cytoplasmic binding domain of a β integrin subunit for binding of ERK2 to inhibit at least one protein kinase, other than a MAP kinase, in a cell activation pathway of the cancer cell. The protein kinases inhibited by the polypeptide may be selected from the group consisting of c-Raf, MEK 1 and kinases in the Src, PI3K, PKB/AKT and PKC families. Methods for the prophylaxis and treatment of cancer are also provided. | 11-01-2012 |
| 20120302508 | SUSTAINED-RELEASE FORMULATION - The present invention relates to a sustained-release formulation comprising a metastin derivative and a lactic acid-glycolic acid copolymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof. The sustained-release formulation of the present invention slowly and stably release compound (I) or a salt thereof for a long time and exerts a medicinal effect of compound (I) or a salt thereof for a long time. Furthermore, the sustained-release formulation of the present invention, which improves patient's convenience by reducing the number of administration times, is an excellent formulation as a clinical medicine. | 11-29-2012 |
| 20120258920 | PEPTIDES AND APTAMERS THEREOF AS SPECIFIC MODULATORS OF MUTANT P53 FUNCTION - Mutations in the p53 tumor suppressor gene are frequently found in human tumors and mutant p53 proteins actively collaborate with tumor progression. Interfering with mutant p53 function may represent a valid strategy to block tumor growth and development of aggressive phenotypes. As a consequence of the characteristic of peptide aptamers (PAs) to efficiently and selectively bind a target protein, they are able to interfere with its function and in its ability to interact with other partners. In the present application isolated peptides and aptamers thereof able to interact with structural and conformational p53 mutants within the region of the wild-type p53 DNA binding core domain comprised from amino acids 74 to amino acids 298 using the yeast two-hybrid method are disclosed. These PAs are able to efficiently recognize several different p53 point mutants but not wild-type p53. Therefore the peptides and aptamers identified can be useful as inhibitors of mutant p53-associated pro-oncogenic functions for anticancer therapy or as diagnostic tools for mut-p53 or wild-type p53 or as template for designing new peptido-mimetic drugs able to specifically target tumor cells. | 10-11-2012 |
| 20110144031 | Pharmaceutical composition for inducing damages of endothelial cells and treating tumor and method for treating tumor by using the same - The present invention relates to a pharmaceutical composition for inducing damages of endothelial cells, a pharmaceutical composition for treating a tumor, and a method for treating a tumor by using the same. In addition, the pharmaceutical compositions for inducing damages of endothelial cells comprises: an effective amount of Concanavalin A (Con A). | 06-16-2011 |
| 20110166078 | OLIGOSACCHARIDE COMPOUNDS FOR USE IN MOBILISING STEM CELLS - A compound of the following formula or a salt, solvate or formula (I) and a pharmaceutical composition containing said compound. It concerns also its use in the treatment of cancer and/or of pathological angiogenesis and/or in promoting the mobilisation of stem cells, in particular hematopoietic stem cells. | 07-07-2011 |
| 20160075736 | Process for the Preparation of Bortezomib Mannitol Ester - A novel and improved process for preparation of bortezomib mannitol ester is derived, which process avoids excessive use of solvents, involves convenient, industrially feasible and economical techniques, and provides improvements in purity over processes known in the art. | 03-17-2016 |
| 20110224148 | CARBOHYDRATE-POLYAMINO ACID-DRUG CONJUGATES - Compositions that include a polymer conjugate and glucosamine operatively associated with the polymer conjugate, wherein the polymer conjugate includes a first drug, are described herein. Also disclosed herein are methods of using such compositions to treat, ameliorate, or diagnose a disease or condition such as cancer. | 09-15-2011 |
| 20110130342 | PEPTIDE HOMING TO BRAIN TUMORS - The present invention relates to a peptide, which specifically homes to the intracranial, early stage astrocytoma model that grows as islets and harbors co-opted tumor vessels in the brain. The peptide finds its use in targeted delivery of therapeutic substances to invasive brain cancer or metastatic brain lesions as such and in combination with conventional therapies, such as surgery and radiation, and anti-angiogenic therapies, and as a tool in diagnosis of, e.g., invasive brain cancer or metastatic brain lesions. | 06-02-2011 |
| 20110130341 | METHOD AND KIT FOR DETECTION OF CANCER, AND THERAPEUTIC AGENT FOR CANCER - The object aims to comprehensively analyze miRNA that undergoes epigenetic silencing in cancer to identify miRNA associated with cancer, elucidate the role of the identified miRNA in cancer, and develop a novel method for detecting cancer and a novel therapeutic agent for cancer both of which relate to the miRNA. Disclosed is a method for detecting cancer in a subject, which comprises detecting methylated CpG in a CpG island located in a promoter region of a microRNA 34b gene and/or a microRNA 34c gene in a biological sample collected from the subject. Also disclosed is a therapeutic agent for cancer, which comprises a nucleic acid encoding a BTG4 gene or BTG4, or comprises a nucleic acid encoding a miR-34b gene and/or an miR-34c gene or miR-34b and/or miR-34c. | 06-02-2011 |
| 20110237518 | METHOD FOR TREATING OR PREVENTING BLADDER CANCER USING THE DEPDC1 POLYPEPTIDE - The present invention provides therapeutic agents and methods for treating cancer using the polypeptides posed of an amino acid sequence which includes a polypeptide fragment of DEPDC1. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine. Furthermore, the present invention provides methods of screening for therapeutic agents or compounds useful in inhibition of the DEPDC1/ZN-F224 complex formation or the treatment of cancer. The present invention also provides siRNAs targeting the ZNF224 gene, which are suggested to be useful in the treatment of bladder cancer. | 09-29-2011 |
| 20110237520 | Anticancer Compounds - Compounds of general formula I: | 09-29-2011 |
| 20110237519 | Hematopoietic Growth Factor Inducible Neurokinin-1 Gene and Uses Thereof - The present invention discloses the cloning of a new cDNA, HGFIN, from stimulated bone marrow stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene, HGFIN, encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is implicated in the treatment of hyperproliferative disorders, particularly bone and breast cancer, because it acts to suppress the proliferating cells. | 09-29-2011 |
| 20140187495 | METHODS FOR TREATING GLIOBLASTOMA - Described are methods for treating cancers, e.g., glioblastoma, including administering an inhibitor of Notch signalling, e.g., a gamma secretase inhibitor, in combination with a chemotherapeutic agent. | 07-03-2014 |
| 20110251135 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS - Disclosed compositions and methods for inhibiting NF-κB mediated cellular proliferation and metastasis. | 10-13-2011 |
| 20110218155 | CHEMICAL MODULATORS OF PRO-APOPTOTIC BAX AND BCL-2 POLYPEPTIDES - The invention provides a method for identifying a compound which modulates the activity of a BCL-2 family polypeptide, the method comprising: a) contacting said BCL-2 family polypeptide with a compound under conditions suitable for modulation of the activity of said BCL-2 family polypeptide; and b) detecting modulation of the activity of said BCL-2 family polypeptide by the compound, wherein the compound interacts with a binding site comprising one or more of an α1 helix, α2 helix, a loop between α1-α2, α.6 helix, and select residues of α4, α.5, and α.8 helices in said BCL-2 family polypeptide; wherein the interaction of the compound with the binding site occurs at a horizontal hydrophobic groove with or without a perimeter of charged and hydrophilic residues, a superior juxta-loop, an inferior juxta-loop, or combination thereof. | 09-08-2011 |
| 20110207676 | Glycosylation of Molecules - Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders. | 08-25-2011 |
| 20110207675 | GENE FUSION TARGETED THERAPY - The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to recurrent gene fusions as clinical targets for prostate cancer. | 08-25-2011 |
| 20110207673 | METHODS AND COMPOSITIONS FOR MODULATING DRUG-POLYMER ARCHITECTURE, PHARMACOKINETICS AND BIODISTRIBUTION - Drug-polymer chemotherapeutics are provided having improved therapeutic efficacy and reduced dose-limiting toxicity. Methods are also provided for modulating the architecture, pharmacokinetics and biodistribution of drug-polymers and for reducing the dependence of transition temperature on concentration for drug-polymers. | 08-25-2011 |
| 20110152199 | CDCA1 PEPTIDE AND PHARMACEUTICAL AGENT COMPRISING THE SAME - The present invention provides the peptide of (A) or (B) below, and methods of using the peptide:
| 06-23-2011 |
| 20110160146 | Conjungation of Small Molecules to Octaarginine Transporters for Overcoming Multi-Drug Resistance - Many cancer therapeutic agents elicit resistance that renders them ineffective and often produces cross resistance to other drugs. One of the most common mechanisms of resistance involves P-glycoprotein (Pgp) mediated drug efflux. Here we provide compositions and methods that restore the efficacy of a therapeutic agent reduced by resistance by conjugation of the same agent to an oligoarginine transporter comprising from about 5 to about 25 guanidino or amidino moieties. We specifically show that the widely used chemotherapeutic agent taxol, ineffective against taxol-resistant human ovarian cancer cell lines, can be incorporated into an octaarginine conjugate that is effective against the same taxol-resistant cell lines. Significantly, the ability of the taxol conjugates to overcome taxol resistance is observed both in cell culture and in animal models of ovarian cancer. The generality and mechanistic basis for this effect were also explored with other Pgp substrate. This approach shows generality for overcoming the multidrug resistance elicited by small molecule cancer chemotherapeutics and could improve the prognosis for many cancer patients and fundamentally alter search strategies for novel therapeutic agents effective against resistant disease. | 06-30-2011 |
| 20110178026 | RICIN-LIKE TOXINS FOR TREATMENT OF CANCER - The present invention provides a protein having chain of a ricin-like toxin, a B chain of a ricin-like toxin and a novel heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a specific protease such as those found in inflammatory cells and cancer cells. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. Also provided is a method of inhibiting or destroying cells having a specific protease, such as cancer cells or inflammatory cells utilizing the nucleic acid molecules and proteins of the invention and pharmaceutical compositions for treating human inflammation and cancer. | 07-21-2011 |
| 20110183916 | Apo-2 Ligand - A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided. | 07-28-2011 |
| 20110183915 | Small Molecule Cancer Treatments that cause Necrosis in Cancer Cells but do not Affect Normal Cells - A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition. | 07-28-2011 |
| 20110269697 | ORGANOARSENIC COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER - A method for treating a lymphoma selected from non-Hodgkin's and Hodgkin's lymphoma comprising administering an organoarsenic compound having a structure of the formula (I) wherein X is S or Se and R | 11-03-2011 |
| 20110275574 | METHOD OF INHIBITING PROLIFERATION OF HEPATIC STELLATE CELLS - There is presently provided a method of inhibiting proliferation of a hepatic stellate cell comprising directly down-regulating the hepatic stellate cell proliferation activity of connexin-43 in the hepatic stellate cell for the treatment of hepatic fibrosis or related disorder. This method primarily involves down regulating connexin-43 with agents such as Snai1, siRNAs, antisense RNA and DNA enzymes directed against the connexin-43 transcript. As a result the proliferation of activated hepatic stellate cells is down regulated. | 11-10-2011 |
| 20160143916 | BROMODOMAIN INHIBITORS - The present invention provides for compounds of formula (I) | 05-26-2016 |
| 20160145313 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present invention provides compositions and methods of treating MUC16 expressing cancer. | 05-26-2016 |
| 20160145302 | A SHORT PEPTIDE TARGETING EPS8 BINDING WITH EGFR AND USE THEREOF - The present invention discloses a short peptide targeting EPS8 binding with EGFR and use thereof, and sequence of the short peptide is N′-Arg-Lys-Lys-Asn-Lys-Pro-Pro-Pro-Pro-Lys-Lys-C′. The short peptide can effectively inhibit proliferation of EPS8 positive tumors, and can also be used to make a pharmaceutical preparation for treating EPS8 positive tumors, which has the potential of being developed into anti-cancer peptide inhibitor drugs. | 05-26-2016 |
